{
  "metadata": {
    "timestamp": "2025-12-17T21:49:11.802908",
    "genes": [
      "CAMK2D",
      "MIR4435-2HG",
      "CDK6",
      "CYTOR",
      "CHRM3",
      "RGS6",
      "KIAA1211L",
      "KLHL4",
      "CDH2",
      "HIVEP3",
      "SPRY4",
      "TRIO",
      "ADAMTS9",
      "WWTR1",
      "SPRED2",
      "VAV3",
      "PLAT",
      "SATB2",
      "CHRM3-AS2",
      "SIPA1L1",
      "GAP43",
      "KCNIP1",
      "PCNX2",
      "GRIA3",
      "ILDR2",
      "IL1RAP",
      "AC092691.1",
      "CPNE4",
      "IQGAP2",
      "BCAT1",
      "TRIM9",
      "LRATD1",
      "NOVA1",
      "METTL7B",
      "JAG1",
      "DENND2A",
      "PALM2-AKAP2",
      "SPRED1",
      "NRCAM",
      "FREM2",
      "DPF3",
      "SPATA6",
      "CNKSR2",
      "HS2ST1",
      "TNFRSF12A",
      "GLDC",
      "MYO16",
      "CHL1",
      "CDK14",
      "CDH4",
      "NEK6",
      "STK17A",
      "STK32A",
      "STK32B",
      "MED12L",
      "CAMK2B",
      "ARHGEF26",
      "ARSJ",
      "C6ORF141",
      "GALR1",
      "PTPRZ1",
      "SH3PXD2B",
      "RHOJ",
      "SHROOM3",
      "ITGB8",
      "CREB5",
      "AC092958.1",
      "INSYN2A",
      "LYST",
      "CSMD2",
      "ITGA3",
      "ITGA7",
      "KLHL29",
      "AC124254.2",
      "DPP6",
      "KANK1",
      "ZDHHC14",
      "PREX1",
      "P2RY14",
      "AC004828.2",
      "SLC35F1",
      "CPNE8",
      "TANC1",
      "IGF2BP2",
      "EML4",
      "ADAM19",
      "COL22A1",
      "ACSS3",
      "SRPX",
      "FRMD5",
      "MEIS1",
      "ESR2",
      "SEMA5A",
      "ENC1",
      "SYNJ2",
      "COL4A2",
      "MEG8",
      "SEMA3E",
      "MAP3K1",
      "POSTN",
      "DLC1",
      "DNMBP",
      "ETV5",
      "DEC1",
      "ABCC3",
      "LONRF2",
      "CEMIP",
      "LINC02742",
      "SHISA9",
      "ETV6",
      "MAMLD1",
      "ERI1",
      "FGF14",
      "SNTG1",
      "FNDC3B",
      "CLMN",
      "SPRY2",
      "PRAG1",
      "SLC8A1",
      "LSAMP",
      "LMO2",
      "DNM1",
      "PDE8A",
      "AC087564.1",
      "GRIK2",
      "RCAN1",
      "GRIN2B",
      "ALK",
      "VMP1",
      "AL356124.1",
      "LEF1",
      "HMGA2",
      "HMGA2-AS1",
      "LDLRAD3",
      "IGF2BP3",
      "PCDH7",
      "LAMC1",
      "PCDH9-AS2",
      "TRPM3",
      "ACSBG1",
      "NES",
      "ADGRL3",
      "ADAM12",
      "HS3ST5",
      "ADAMTS9-AS1",
      "MTCL1",
      "UBASH3B",
      "ARHGAP26",
      "RASSF8",
      "AC017002.5",
      "PGAP1",
      "LIMK1",
      "RYR3",
      "AC060834.2",
      "ZMAT4",
      "KCNMA1",
      "SCD5",
      "SAMD4A",
      "RUNX1",
      "NPAS3",
      "AC064875.1",
      "SCG2",
      "GAS2",
      "OSBP2",
      "PDGFA",
      "LAMA4",
      "SLC35F4",
      "EMP1",
      "KCND2",
      "DPYSL5",
      "RFFL",
      "KALRN",
      "ITPR2",
      "LAMA2",
      "SLC1A2",
      "ELOVL2",
      "L3MBTL4",
      "DPY19L1",
      "RBPMS",
      "RGS17",
      "LPAR1",
      "DUSP6",
      "LINC01138",
      "RNF157",
      "PXYLP1",
      "LHFPL6",
      "FBN2",
      "RUBCNL",
      "FGFR1",
      "SH3KBP1",
      "GRB10",
      "GPR158",
      "LINC01798",
      "EPHA3",
      "PTPRJ",
      "GNG12-AS1",
      "PRKD1",
      "PVT1",
      "LINC00266-1",
      "SEMA3A"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_7",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex request asking me to perform a comprehensive literature analysis of a gene list in the context of astrocytoma. Let me break down what I need to do:\n\n1. Analyze 169 genes provided in the gene list\n2. Context is Astrocytoma (a brain tumor of astrocyte origin)\n3. I need to identify gene programs - clusters of genes working together\n4. Provide both a detailed narrative report (10,000+ words) and JSON output\n5. Ground everything in the provided search results and literature evidence\n\nLet me first assess the search results I have. Looking through them, I see many NCBI gene databases, some Nature articles about gliomas, astrocytes, tumoroids, and various brain-related studies. Key relevant papers include:\n- [3] TRIM24::NTRK2 fusion in tumors with targeted treatment\n- [5] Patient-derived tumoroids from pediatric brain tumors\n- [13] Pericytes in glioma microenvironment \n- [14] Astrocyte activation post-TBI with neuroinflammation\n- [16] Basement membrane genes in glioblastoma\n- [25] Astrocyte activation and transcriptional changes\n\nThe genes in the input list are involved in various processes. Let me categorize them conceptually:\n\n**Cellular Adhesion & Cytoskeleton:**\n- CDH2, CDH4 (cadherins)\n- ITGB8, ITGA3, ITGA7 (integrins)\n- NRCAM, NCAM-like\n- KALRN, SHROOM3, LIMK1 (cytoskeleton)\n- ARHGEF26, RHOJ, VAV3 (Rho GTPases)\n\n**Calcium/Ion Channels:**\n- CAMK2D, CAMK2B (calcium/calmodulin kinases)\n\n\n- TRPM3, KCND2, KCNMA1, KCNIP1 (ion channels)\n- GRIA3, GRIN2B (glutamate receptors)\n\n**Growth Factor Signaling:**\n- SPRY2, SPRY4, SPRED1, SPRED2 (negative regulators of RTK signaling)\n- PDGFA\n- FGF14, FGFR1\n- JAG1 (Notch signaling)\n- SEMA3A, SEMA5A, SEMA3E (semaphorins)\n\n**Kinases/Phosphorylation:**\n- CDK6, CDK14 (cyclin-dependent kinases)\n- NEK6, STK17A, STK32A, STK32B (other kinases)\n- PRKD1\n\n**Transcription Factors:**\n- RUNX1, LEF1, CREB5 (transcriptional regulators)\n- ETV5, ETV6 (ETS family)\n- SATB2\n\n**Cell-Cell Communication:**\n- CHRM3 (muscarinic receptor)\n- P2RY14 (purinergic signaling)\n- JAG1 (Notch)\n\n**Neural Differentiation/Development:**\n- GAP43, KALRN, SNTG1 (neurite outgrowth)\n- NOVA1, RBPMS (RNA-binding proteins)\n- LSAMP, LMO2\n\n**Extracellular Matrix & Adhesion:**\n- ADAMTS9, ADAM12, ADAM19\n- COL22A1, COL4A2 (collagens)\n- FBN2 (fibrillin)\n- POSTN (periostin)\n\n**Metabolic Processes:**\n- GLDC (glycine decarboxylase)\n- BCAT1 (branched-chain amino acid transaminase)\n- SCD5\n\n**Wnt Pathway:**\n- LEF1, CTNNBIP1\n- RGS6\n\n**Non-coding RNAs:**\n- MIR4435-2HG, CHRM3-AS2, ADAMTS9-AS1, HMGA2-AS1, PCDH9-AS2\n\n, GNG12-AS1, LINC02742, LINC01138, LINC01798, LINC00266-1, MEG8\n\n**Additional Genes:**\n- VMP1, LYST, UBASH3B, ERI1, ALK, GRIK2\n\nI need to organize these into functional programs relevant to astrocytoma biology. Since astrocytomas originate from glial cells and range from low to high grade, I should map genes to processes like cell adhesion and migration, receptor signaling pathways, calcium-dependent differentiation, and neural differentiation programs. The long non-coding RNAs likely regulate multiple pathways, while the metabolic genes suggest altered nutrient utilization typical of transformed cells.\n\nBeyond growth signaling, I should consider programs for cell-cell communication through gap junctions, metabolic shifts in amino acid handling, ion regulation that astrocytes normally perform, extracellular matrix degradation for invasion, transcriptional control of stemness, and epithelial-mesenchymal transition features that enable tumor progression.\n</think>\n\n# Comprehensive Functional Analysis of Astrocytoma-Associated Gene Programs\n\nThis analysis systematically characterizes 169 genes within the context of astrocytoma biology, identifying twelve distinct gene programs that collectively govern cellular adhesion, growth factor signaling, neural differentiation, metabolic adaptation, and tumor progression. Through integration of current literature with pathway-level analysis, the study reveals that while individual genes have well-characterized functions, their coordinated activity within astrocytoma cells produces emergent phenotypes critical to tumor initiation and progression. The most significant programs include adhesion and cytoskeletal reorganization, growth factor receptor signaling dynamics, calcium-mediated differentiation control, and metabolic reprogramming toward amino acid anabolism. Notably, multiple genes encoding semaphorin guidance proteins and their modifiers suggest that astrocytoma cells exploit developmental axon guidance machinery for invasion and migration, while coordinated expression of calcium channels and kinases indicates aberrant activation of neural differentiation programs even within neoplastic contexts. The identification of non-coding RNA regulators alongside protein-coding genes emphasizes the multi-layered transcriptional dysregulation characteristic of these tumors. Integration of these programs into broader pathogenic models of astrocytoma should prioritize the dysregulation of receptor tyrosine kinases, the aberrant activation of developmental transcriptional networks, and the tumor microenvironment-instructive roles of adhesion and secreted proteins.\n\n## Cellular Adhesion and Cytoskeletal Organization in Astrocytoma\n\nThe astrocytic cell surface is fundamentally organized by adherens junctions and integrin-based focal adhesions, which serve not only structural roles but also act as biochemical signaling hubs controlling cell fate. Within the input gene list, multiple cadherins and calcium-dependent kinases establish a core adhesion program essential for both normal astrocyte physiology and pathological transformation. **CDH2** (N-cadherin) encodes the primary adherens junction protein in neural tissues and mediates homophilic cell-cell contacts critical for maintaining neural tissue integrity[14]. In astrocytoma, altered CDH2 expression frequently accompanies epithelial-to-mesenchymal transition (EMT)-like phenotypes that promote invasion and reduced contact inhibition. **CDH4** (R-cadherin) operates in parallel and often shows compensatory upregulation when classical N-cadherin signaling is perturbed[57]. The calcium-dependent kinases **CAMK2D** and **CAMK2B** function downstream of cadherins by integrating calcium influx with adhesion complex remodeling; these kinases phosphorylate numerous cytoskeletal regulators and are particularly important during developmental phases of neural circuit formation that astrocytomas often recapitulate[10]. Complementing this are **KALRN** (kalirin), which encodes a Rho guanine nucleotide exchange factor (GEF) that regulates actin polymerization and spine morphogenesis, and **RHOJ**, a small GTPase that controls filopodial dynamics[33][36]. **LIMK1** links Rho signaling to actin dynamics through LIM kinase activity, which phosphorylates cofilin and stabilizes F-actin structures[6]. **SHROOM3**, encoding a protein that organizes the actin cytoskeleton via formin interactions, regulates cell shape changes and migration in multiple cancer contexts. These cytoskeletal regulators collectively enable the morphological plasticity characteristic of invasive astrocytoma cells, allowing transition between ramified (migratory) and stellate (differentiated-like) morphologies.\n\nThe integrin-mediated focal adhesion complex represents a second major component of the astrocytic adhesion apparatus, and multiple integrin subunits appear in the gene list. **ITGB8**, **ITGA3**, and **ITGA7** encode integrin heterodimer components that facilitate interaction with basement membrane proteins and regulate mechanotransduction[4][6]. In astrocytomas, altered integrin expression correlates with invasive phenotypes and therapeutic resistance, particularly when coupled to changes in the extracellular matrix (ECM) composition[13]. **ARHGEF26** encodes a Rho GEF downstream of integrin signaling and amplifies Rho-dependent responses to mechanical and ligand-driven stimuli. **VAV3**, another GEF, coordinates integrin and growth factor receptor signaling through common Rho/Rac effectors. The coordinated activity of these adhesion molecules and their associated kinases enables astrocytoma cells to remodel their microenvironment, detach from neighboring cells, and acquire migratory capacity while maintaining selective adhesion to tumor-supportive stromal elements.\n\nWithin this adhesion program, **NRCAM** (neuron-cell adhesion molecule, also known as CNTNAP2) serves a specialized role as an L1-family adhesion molecule promoting neurite outgrowth and axonal guidance in normal neural development. In astrocytomas, altered NRCAM expression may reflect aberrant reactivation of developmental neural programs, potentially contributing to pseudopodia formation and invasive branching morphologies[14]. **PCDH7** and related protocadherins function as homophilic adhesion molecules with roles in neural circuit assembly and may similarly contribute to heterotypic astrocyte-neuron or astrocyte-astrocyte contacts within tumors. The integrin-linked kinase (**ILK**, referenced in NCBI records as a focal adhesion adaptor) likely coordinates with these adhesion proteins through heterotrimeric complexes with PINCH and Parvin, translating mechanical signals from the ECM into intracellular responses[6]. Together, this constellation of adhesion molecules and cytoskeletal regulators constitutes a **Cellular Adhesion and Cytoskeletal Reorganization** program that fundamentally governs astrocytoma invasiveness, therapeutic response to mechanotransduction inhibitors, and the tumor's ability to remodel its microenvironment.\n\n## Growth Factor Receptor Signaling and Pathway Dynamics\n\nAberrant receptor tyrosine kinase (RTK) signaling represents one of the hallmark features of astrocytomas, and the gene list contains multiple regulators of this critical signaling axis. **FGFR1** (fibroblast growth factor receptor 1) is frequently dysregulated in pediatric and adult astrocytomas through gene amplification, overexpression, or fusion events, driving constitutive activation of downstream MAPK and PI3K/AKT pathways[5][18]. **FGF14**, encoding an atypical FGF family member, may serve autocrine or paracrine functions to maintain FGFR signaling. **PDGFA** (platelet-derived growth factor alpha) encodes a ligand whose overexpression is particularly common in high-grade gliomas and promotes astrocyte proliferation, survival, and angiogenesis; its receptor **PDGFRA** is also frequently altered in these tumors, though not directly in the input list, highlighting the central role of this pathway in astrocytoma pathogenesis[15][52].\n\nCritically, the input list contains multiple negative regulators of RTK signaling that are frequently dysregulated or lost in astrocytoma. **SPRY2**, **SPRY4**, **SPRED1**, and **SPRED2** all encode secreted or intracellular inhibitors of RTK signaling, acting through competition for adapter proteins or direct inhibition of Ras/MAPK cascade components[37]. Reduced expression of these \"brake\" molecules is common in high-grade gliomas and contributes to unopposed RTK signaling. Conversely, when present at abnormal levels, these genes may be functionally inactivated through epigenetic mechanisms or transcriptional dysregulation. **DUSP6**, encoding a phosphatase that dephosphorylates ERK1/2, similarly attenuates MAPK signaling but is frequently downregulated in gliomas[25]. The coordinated loss or silencing of these negative regulators, coupled with amplification of positive RTK effectors, creates a permissive environment for sustained MAPK and PI3K/AKT activation even in the absence of excessive ligand production.\n\nDownstream of these RTKs, the cascading activation of MAPK and PI3K pathways drives proliferation, survival, and metabolic reprogramming. While **MAPK1** (ERK2) itself is not in the input list, multiple downstream effectors are present. **PRKD1** (protein kinase D1) integrates MAPK signaling with calcium-dependent responses and controls transcriptional programs regulating cell proliferation and differentiation. **CREB5** (CREB family transcription factor) is a key target of kinase cascades downstream of RTKs and controls expression of genes promoting survival and proliferation. **ETV5** and **ETV6**, members of the ETS transcription factor family, are direct targets of MAPK signaling and drive expression of genes promoting cellular plasticity and stemness. In astrocytomas, particularly those harboring BRAF mutations or KIAA1549::BRAF fusions, ETS factors become particularly active in promoting undifferentiated phenotypes[5]. The presence of **RUNX1** in the gene list further suggests integration with Wnt and Notch signaling pathways, as RUNX1 frequently cooperates with LEF1 (also in the list) to promote proliferation in neural progenitor-like states.\n\nA particularly important sub-program within RTK signaling involves the **TRIM9** gene, which encodes an E3 ubiquitin ligase regulating endosomal trafficking of RTK signaling components. TRIM9 controls the balance between recycling receptors back to the cell surface (sustaining signaling) versus their degradation (terminating signaling). Dysregulation of TRIM9 in astrocytomas may permit sustained RTK activity despite ligand withdrawal or attempted receptor internalization. Additionally, **IQGAP2**, a scaffolding protein related to IQGAP1, integrates RTK signaling with small GTPase (Rac/Rho) pathways, enabling cross-talk between adhesion and growth factor signaling[56]. Together, these components constitute a **Growth Factor Receptor Signaling and Pathway Dynamics** program that explains the exquisite sensitivity of astrocytomas to RTK inhibitors in some contexts and their remarkable capacity for pathway reactivation through compensatory mechanisms in others.\n\n## Calcium Signaling, Differentiation Control, and Neuronal Phenotype Reversion\n\nAstrocytes are classically defined as non-excitable neural cells, yet they possess sophisticated calcium signaling machinery and, under certain developmental or pathological conditions, can exhibit calcium dynamics reminiscent of neurons. The input gene list contains a rich assemblage of calcium-handling proteins, suggesting that aberrant calcium signaling may drive astrocytoma phenotypes. At the core are three genes encoding ionotropic glutamate receptors: **GRIN2B** (NMDA receptor subunit 2B), **GRIA3** (AMPA receptor subunit 3), and **GRIK2** (kainate receptor subunit). In normal mature astrocytes, these receptors are typically silent or express at very low levels; their upregulation in astrocytomas may reflect trans-differentiation or developmental arrest at an immature glial progenitor state[7][10]. **GRIN2B** in particular is frequently elevated in schizophrenia and other neuropsychiatric conditions associated with glutamate dysregulation, and its expression in astrocytoma may similarly indicate aberrant glutamate signaling and altered responsiveness to synaptic neurotransmitter[10].\n\nComplementing these ionotropic receptors are multiple ion channels regulating calcium and potassium dynamics. **TRPM3**, a member of the transient receptor potential melastatin family, is a calcium-permeable cation channel whose activation elevates intracellular calcium and triggers downstream transcriptional responses. **KCND2** and **KCNMA1** encode potassium channels that, while not directly calcium-permeable, regulate the electrical driving force for calcium entry through voltage-gated calcium channels and thereby modulate calcium-dependent signaling[7]. **KCNIP1** encodes a potassium channel interacting protein that modulates Kv4 channel function. The coordinated activity of these channels, along with **ITPR2** (inositol 1,4,5-trisphosphate receptor 2), which releases calcium from intracellular stores, creates a calcium signaling microenvironment distinct from that of normal mature astrocytes.\n\nCalcium influx through these channels and receptors activates multiple downstream effectors, foremost among which are the calcium/calmodulin-dependent kinases **CAMK2D** and **CAMK2B**. These kinases phosphorylate numerous transcription factors and synaptic proteins, and their sustained activation in astrocytomas may drive expression of genes promoting neural differentiation or neuronal identity. Supporting this interpretation is the presence of **KALRN** (kalirin), a RhoGEF that is particularly critical for dendritic spine formation in neurons and can be activated downstream of NMDA receptors. **NOVA1** (neuro-oncology ventral antigen 1), an RNA-binding protein, is another calcium-dependent factor frequently elevated in neurons and neural progenitors; its appearance in the astrocytoma gene list suggests that calcium-driven splicing programs may drive expression of neuronal isoforms of proteins. **RBPMS** (RNA-binding protein with multiple splicing domains) similarly participates in calcium-dependent transcriptome remodeling and has been associated with neuronal differentiation.\n\nIn this calcium-centered program, **RYR3** (ryanodine receptor 3) encodes a calcium release channel in the endoplasmic reticulum, providing an alternative route for calcium mobilization independent of IP3 receptors. The activation of RYR3, often driven by calcium-induced calcium release (CICR) mechanisms initiated by influx through plasma membrane channels, can amplify calcium oscillations and drive transcriptional changes. **SLC8A1** (solute carrier family 8 member 1, also known as NCX1), encoding the sodium-calcium exchanger, bidirectionally couples sodium and calcium gradients; its dysregulation in astrocytomas may alter the threshold for calcium-dependent gene expression. Collectively, this **Calcium Signaling, Differentiation Control, and Neuronal Phenotype Reversion** program reveals a striking finding: astrocytomas may retain and pathologically activate developmental programs that normally guide neural progenitor cells toward differentiation, but in the tumor context, these programs drive proliferation, stemness, and invasive phenotypes rather than terminal maturation. This highlights the hypothesis that astrocytomas may represent a developmental \"trap\" wherein normal differentiation cues are uncoupled from their growth-suppressive effects.\n\n## Semaphorin-Based Axon Guidance and Cell Migration\n\nBeyond their classical roles in axon guidance during neural development, semaphorins and their receptors have emerged as critical regulators of cancer cell migration and invasion. The input gene list contains three semaphorin genes (**SEMA3A**, **SEMA5A**, **SEMA3E**) and multiple genes encoding regulators of semaphorin signaling. **SEMA3A** encodes a secreted semaphorin that signals through neuropilin and plexin receptors to mediate growth cone collapse and axon repulsion in developing neurons; in astrocytomas, aberrant SEMA3A expression may dysregulate tumor cell motility by providing false developmental guidance cues[37]. **SEMA5A** and **SEMA3E** similarly encode secreted semaphorins with roles in guiding cell migration and tissue patterning. Critically, the presence of **TRIO** in the gene list is particularly significant, as TRIO encodes a large GEF protein that interacts with CRMP2 (collapsin response mediator protein 2) to coordinate cytoskeletal responses to semaphorin signaling[37]. In the normal developmental context, semaphorin-induced phosphorylation of CRMP2 (to form pCRMP2) recruits Trio, which then suppresses filopodial activity and drives growth cone collapse. In astrocytomas, dysregulation of this axis could result in uncontrolled filopodial dynamics promoting invasion, or conversely, could lock cells in a non-motile state depending on the specific alterations in semaphorin, receptor, or effector expression.\n\nSupporting this semaphorin program are multiple cytoskeletal regulators: **LIMK1** (which phosphorylates cofilin downstream of semaphorin signaling to stabilize actin filaments), **RHOJ** (which regulates filopodial actin polymerization), and **VAV3** (which coordinates Rac activation downstream of guidance cues). **ARHGAP26** encodes a RhoGAP that may suppress Rho activity in response to repulsive guidance cues, allowing cytoplasmic relaxation and reduced contractility. The coordination of these factors suggests that astrocytomas can pathologically activate developmental axon guidance machinery, employing semaphorin-Plexin-Trio-CRMP2 signaling to choreograph invasion through neural tissue. This is particularly relevant in the context of infiltrative astrocytomas, which characteristically invade along white matter tracts and neuronal fiber bundles—anatomical structures that themselves are organized by developmental guidance cues. The **Semaphorin-Based Axon Guidance and Cell Migration** program thus represents a key innovation by which astrocytomas exploit normal developmental programs for pathological advantage.\n\n## Neural Differentiation Markers and Developmental Transcriptional Networks\n\nAstrocytomas frequently exhibit transcriptional signatures reminiscent of neural progenitor cells or immature astrocytes, suggesting a reactivation of developmental transcriptional networks. The input gene list contains numerous transcription factors and epigenetic regulators that orchestrate these programs. **SATB2** (special AT-rich sequence-binding protein 2) is a chromatin-associated protein known to regulate neural lineage commitment and is particularly important in determining neuronal versus oligodendroglial fates during development[5]. **LEF1** (lymphoid enhancer-binding factor 1) is a member of the TCF/LEF family of transcription factors and a key effector of canonical Wnt signaling; its roles in promoting stemness and maintaining progenitor identity are well-established[59]. **RUNX1** (runt-related transcription factor 1) cooperates with LEF1 and other factors to drive hematopoietic and neural progenitor differentiation, and its dysregulation in astrocytomas may inappropriately activate stemness programs[41].\n\nThe **ETV5** and **ETV6** genes encode ETS-domain transcription factors that are direct targets of MAPK signaling and promote expression of genes associated with cellular plasticity and developmental plasticity. **CREB5** (cAMP response element binding protein 5) is activated downstream of calcium and MAPK signaling, and drives expression of genes promoting proliferation and survival. In combination, these transcriptional regulators create a permissive chromatin and transcriptional landscape favoring proliferation and reduced differentiation. Notably, **DPF3** encodes a component of the BAF chromatin remodeling complex, which regulates access to developmentally regulated genes; dysregulation of DPF3 or other BAF subunits (not in the input list) could alter the accessibility of developmental loci and contribute to inappropriate neural differentiation programs in astrocytomas[5].\n\nAdditionally, multiple genes in the list encode proteins involved in establishing neural identity and differentiation. **GAP43** (growth-associated protein 43) is classically a neuronal marker but can also be expressed in astrocytes under conditions of injury or developmental immaturity[14]. Its presence in the astrocytoma gene list suggests active neurite outgrowth-like programming. **SNTG1** (syntrophin-gamma 1) is similarly associated with neuronal differentiation and axonal outgrowth. **LSAMP** (limbic system-associated membrane protein) and **LMO2** (LIM domain only 2) are neural differentiation markers, and their presence further suggests that astrocytomas revert to immature neural cell transcriptional states. Together, the **Neural Differentiation Markers and Developmental Transcriptional Networks** program reveals that astrocytoma tumorigenesis may involve a profound dysregulation of developmental transcriptional programs, wherein neural progenitor differentiation genes are reactivated to promote proliferation rather than terminal differentiation.\n\n## Extracellular Matrix Remodeling and Invasion\n\nThe tumor microenvironment is fundamentally composed of the extracellular matrix (ECM), and its remodeling by tumor cells is essential for invasion and metastasis. The input gene list is rich in genes encoding ECM-modifying enzymes and ECM proteins themselves. **ADAMTS9** (ADAM metallopeptidase with thrombospondin type 1 motif 9) is a secreted protease that cleaves versican and other proteoglycans, thereby reducing ECM stability and promoting invasiveness[8]. **ADAM12** and **ADAM19** are additional members of the ADAM protease family, with ADAM12 particularly important in promoting invasive phenotypes in multiple cancer types. These proteases collaborate to degrade the basement membrane and tumor stroma, facilitating invasion and providing access to nascent blood vessels.\n\nComplementing the proteases are the structural ECM proteins: **COL4A2** (collagen type IV alpha 2 chain) and **COL22A1** (collagen type XXII) constitute the structural backbone of the basement membrane and dermis, respectively. Paradoxically, while these genes encode ECM components that might seem to oppose invasion, their elevated expression in astrocytomas often correlates with invasion and may reflect fibrotic remodeling of the tumor microenvironment by both tumor cells and recruited stromal fibroblasts. **FBN2** (fibrillin 2) encodes a component of extracellular microfibrils and is frequently elevated in invasive tumors. **POSTN** (periostin) is a matricellular protein that promotes cell adhesion to the ECM and associates with angiogenesis and EMT[13]. **LAMC1** and **LAMA2** encode components of laminins (heterotrimer matrix proteins), and their altered expression or processing by proteases fundamentally changes the biochemical properties of the tumor microenvironment.\n\nNotably, **ADAMTS9-AS1** is a long non-coding RNA antisense to ADAMTS9; such lncRNAs can regulate the stability or localization of their sense strand targets and may represent an additional layer of control over ECM remodeling. In the context of glioblastomas and high-grade astrocytomas, basement membrane invasion is a critical step in vascular co-option and tumor progression, and the coordinated activity of these proteases and ECM proteins governs this process[16]. The **Extracellular Matrix Remodeling and Invasion** program thus represents a multifactorial system wherein tumor-derived and stroma-derived protease activity is balanced against ECM deposition to create a permissive microenvironment for tumor cell infiltration and vascular remodeling.\n\n## Metabolic Reprogramming Toward Amino Acid Anabolism\n\nTumors are characterized by profound metabolic reprogramming, often featuring enhanced glycolysis and altered amino acid metabolism. The input gene list contains several genes directly implicated in amino acid biosynthesis and catabolism. **BCAT1** (branched-chain amino acid transaminase 1) catalyzes the initial step of branched-chain amino acid (BCAA) catabolism, converting BCAAs (leucine, isoleucine, valine) into branched-chain α-ketoacids; elevated BCAT1 is associated with poor prognosis in glioblastomas and promotes anaplerotic replenishment of the tricarboxylic acid cycle[51]. **GLDC** (glycine decarboxylase, also part of the glycine cleavage system) catalyzes the oxidative breakdown of glycine to CO2, ammonia, and a one-carbon unit, thereby contributing to one-carbon metabolism critical for nucleotide and amino acid synthesis. Dysregulation of glycine metabolism is a hallmark of malignant gliomas and promotes tumor growth under hypoxic and nutrient-restricted conditions.\n\n**ACSS3** (acyl-CoA synthetase short chain family member 3) catalyzes the conversion of short-chain fatty acids to acyl-CoA derivatives, enabling their entry into lipid synthesis and energy metabolism pathways. **SCD5** (stearoyl-CoA desaturase 5) catalyzes the desaturation of saturated fatty acids to monounsaturated fatty acids, a critical step in maintaining membrane fluidity and promoting cell survival under stress. These lipogenic enzymes are frequently upregulated in high-grade gliomas and contribute to the Warburg-like metabolic reprogramming observed in these tumors[51]. **OSBP2** (oxysterol-binding protein 2) regulates intracellular lipid transport and may couple lipid sensing to mTOR signaling and proliferation.\n\n**ELOVL2** (ELOVL fatty acid elongase 2) extends long-chain polyunsaturated fatty acids, contributing to specialized membrane lipid synthesis critical for highly branched dendritic and axonal membranes typical of neural cells. The presence of ELOVL2 in the astrocytoma gene list suggests that tumors may maintain neural-like lipid compositions or that lipid remodeling promotes tumor-supportive signaling. **SLC1A2** (solute carrier family 1 member 2, also known as GLT-1/EAAT2) encodes the primary astrocytic glutamate transporter; while not strictly a metabolic enzyme, its dysregulation profoundly impacts glutamate homeostasis and can drive glutamine synthesis, a key anaplerotic amino acid[14]. Collectively, the **Metabolic Reprogramming Toward Amino Acid Anabolism** program reveals that astrocytomas engage in sophisticated metabolic rewiring to fuel rapid proliferation and maintain biosynthetic capacity even under hypoxic and nutrient-restricted tumor microenvironment conditions.\n\n## Ion Channel Regulation and Astrocytic Electrophysiology\n\nAstrocytes in normal brain tissue are characterized by distinctive electrophysiological properties, including strong potassium buffering capacity and minimal intrinsic excitability. Astrocytomas frequently dysregulate ion channels in ways that alter cellular excitability, calcium signaling, and response to microenvironmental cues. Beyond the calcium channels discussed previously, the input list contains multiple potassium channel genes: **KCND2** (Kv4.2, a voltage-gated potassium channel), **KCNMA1** (MaxiK, a large-conductance calcium-activated potassium channel), and **KCNIP1** (an auxiliary subunit modulating Kv4 channel function). **KCNIP1** is particularly important as it regulates the inactivation kinetics of Kv4 channels and controls the temporal window for calcium entry[7].\n\n**TRPM3**, a transient receptor potential melastatin channel, is a polymodal cation channel activated by heat, pregnenolone sulfate, and other ligands; its activation causes calcium influx and downstream activation of MAPK and other signaling cascades. In astrocytomas, aberrant TRPM3 expression may render tumor cells responsive to stimuli that normally do not activate astrocytes, thereby integrating novel environmental signals into proliferation and migration decisions. The presence of **CHRM3**, encoding a muscarinic acetylcholine receptor, is particularly intriguing, as it couples to G-protein signaling and can activate phospholipase C, generating inositol trisphosphate for calcium mobilization and diacylglycerol for protein kinase C activation[1]. Astrocytes express muscarinic receptors in a subtype-specific manner, and their dysregulation in astrocytomas may alter responsiveness to cholinergic innervation or may be secondary to altered neuronal input.\n\n**P2RY14** (purinergic receptor P2Y14) is a metabotropic purine receptor coupled to Gi/o proteins; its activation suppresses cAMP and can modulate cell migration and proliferation. Dysregulation of purinergic signaling is increasingly recognized as contributing to glioma biology, and the presence of P2RY14 suggests that ATP/UTP released by dying cells or activated neurons may aberrantly influence astrocytoma cell behavior. Together, these ion channels and receptors constitute an **Ion Channel Regulation and Astrocytic Electrophysiology** program that fundamentally alters the electrical and chemical responsiveness of astrocytoma cells to their microenvironment.\n\n## Cell-Cell Communication and Paracrine Signaling\n\nBeyond direct cell-cell adhesion, cells communicate through diffusible signals, and the input gene list contains multiple genes regulating such paracrine interactions. **JAG1** (jagged canonical Notch ligand 1) encodes a transmembrane ligand for Notch receptors expressed on neighboring cells; Notch signaling is a critical regulator of cell fate determination during neural development and is frequently dysregulated in astrocytomas to promote stemness[5]. **ALK** (anaplastic lymphoma receptor tyrosine kinase), while primarily known for its role in anaplastic large cell lymphomas and ALK-positive lung cancers, can function as a receptor for ligands including pleiotrophin, and its dysregulation in astrocytomas (particularly in cases with ALK fusions such as GFAP::ALK in infant-type hemispheric gliomas) drives potent oncogenic signaling[5].\n\nThe list includes three genes encoding proteins with roles in Notch and Wnt signaling regulation: **CTNNBIP1** (catenin beta interacting protein 1), **LEF1**, and **RGS6** (regulator of G-protein signaling 6). **CTNNBIP1** and **LEF1** were discussed previously in the context of Wnt signaling; their presence in multiple programs underscores the centrality of Wnt signaling to astrocytoma biology. **RGS6** encodes a GTPase-activating protein for heterotrimeric G proteins, thereby terminating G-protein-coupled receptor signaling; dysregulation of RGS6 may alter the sensitivity of cells to paracrine signals and growth factors[28]. **DENND2A** (DENN domain-containing 2A) encodes a guanine nucleotide exchange factor for Rab GTPases, thereby regulating endocytic trafficking and could influence the processing of growth factor receptors and adhesion molecules. The presence of multiple genes regulating paracrine and juxtacrine signaling suggests that astrocytomas employ sophisticated inter-cellular communication networks to coordinate behavior within multicellular foci or to manipulate their microenvironment.\n\n## Wnt and Notch Signaling Integration\n\nWhile Wnt and Notch signaling are discussed separately in some contexts, in astrocytoma biology they are fundamentally intertwined, and the input gene list contains multiple regulators of both pathways. **LEF1** is a central node in this network, functioning as a co-transcription factor with beta-catenin in the canonical Wnt pathway and serving as a Notch target gene that can cross-regulate between pathways[27][59]. **RUNX1** similarly participates in both Wnt and Notch signaling networks, promoting stemness through interactions with LEF1 and other factors[38][41]. **JAG1**, as discussed above, is a Notch ligand, and its overexpression in astrocytomas correlates with increased stemness and reduced differentiation.\n\nThe **RGS6** gene deserves particular emphasis in this context, as RGS proteins regulate the kinetics of G-protein signaling downstream of various receptors, including those coupled to Wnt and Notch pathways through indirect mechanisms. **CTNNBIP1**, which inhibits beta-catenin-LEF1 interaction, may act as a brake on canonical Wnt signaling; its dysregulation could shift the balance between canonical and non-canonical Wnt signaling. In the input list, the presence of potential Wnt-regulating genes (LEF1, CTNNBIP1, RGS6) alongside genes encoding receptor tyrosine kinases (FGFR1, ALK, PDGFA) and calcium signaling regulators suggests that astrocytomas integrate Wnt/Notch signaling with growth factor and developmental signals to establish a uniquely oncogenic transcriptional state. This integration is particularly relevant in pediatric astrocytomas (pilocytic astrocytomas, diffuse midline gliomas), where Wnt pathway activation often cooperates with MAPK pathway alterations to drive tumorigenesis[5].\n\n## RNA Processing and Post-Transcriptional Gene Regulation\n\nThe input gene list contains multiple genes encoding RNA-binding proteins and proteins regulating RNA metabolism, suggesting that post-transcriptional control is a critical dimension of astrocytoma biology. **NOVA1** (neuro-oncology ventral antigen 1) is an RNA-binding protein that regulates alternative splicing of transcripts encoding ion channels, synaptic proteins, and developmental regulators; its dysregulation in astrocytomas may drive expression of oncogenic isoforms of key proteins[44]. **RBPMS** (RNA-binding protein with multiple splicing domains) similarly regulates alternative splicing and is particularly important in neurons and neural progenitors. **ERI1** (exoribonuclease 1) participates in microRNA biogenesis and degradation, and its dysregulation could alter the abundance of tumor-suppressive or tumor-promoting miRNAs.\n\nThe gene list is notably enriched in long non-coding RNAs (lncRNAs): **MIR4435-2HG**, **CHRM3-AS2**, **ADAMTS9-AS1**, **HMGA2-AS1**, **PCDH9-AS2**, **GNG12-AS1**, **LINC02742**, **LINC01138**, **LINC01798**, **LINC00266-1**, and **MEG8**. LncRNAs can function as molecular scaffolds, competing endoribonucleic acids (ceRNAs), or regulators of chromatin structure and transcription[44][46]. For example, **MEG8** (maternally expressed 8) is an imprinted lncRNA with roles in development and metabolism, and its dysregulation could contribute to loss of imprinting and altered metabolic state in astrocytomas. **LINC01068**, recently identified as dysregulated in schizophrenia with roles in neural stem cell proliferation and differentiation, may similarly contribute to astrocytoma stemness and proliferation[44]. The collective presence of these RNA-binding proteins and lncRNAs constitutes an **RNA Processing and Post-Transcriptional Gene Regulation** program that enables cells to rapidly remodel their proteome in response to microenvironmental changes without requiring new transcription.\n\n## Hypoxia Response and Metabolic Adaptation\n\nWhile hypoxia-inducible factors (HIFs) are not directly represented in the input gene list, multiple genes reflect downstream responses to hypoxic stress and metabolic adaptation to low-oxygen microenvironments characteristic of tumors. **GLDC**, **BCAT1**, **ACSS3**, and related metabolic genes discussed previously are upregulated in hypoxic gliomas to support continued biosynthesis despite reduced oxidative phosphorylation[49]. **RYR3** and **ITPR2**, encoding calcium release channels, may support calcium signaling needed to sustain ATP production and biosynthetic pathways during hypoxic stress. The presence of calcium-calmodulin-dependent kinases (CAMK2D, CAMK2B) further suggests that cells maintain robust calcium and energy sensing even under hypoxic conditions[47].\n\nNotably, several genes have been implicated in regulating responses to mechanical stress and hypoxia simultaneously. **ARHGEF26**, **RHOJ**, and other Rho pathway regulators can be activated by reduced oxygen availability and contribute to metabolic adaptation. The combination of metabolic reprogramming genes with cytoskeletal and adhesion-related genes suggests that astrocytomas coordinate mechanical and metabolic responses to their microenvironment, ensuring that reduced oxygen availability does not compromise cellular integrity or adhesion.\n\n## Signaling Integration and Cross-Talk\n\nA critical insight emerging from the comprehensive gene list is the extensive integration of multiple signaling pathways. Numerous genes function as nodes or hubs that simultaneously participate in multiple pathways. For example, **KALRN** and **TRIO** integrate calcium-dependent and growth factor signaling to control cytoskeletal dynamics. **LIMK1** similarly links Rho signaling, semaphorin responses, and calcium signaling. **CREB5** and **RUNX1** are transcriptional hubs receiving inputs from MAPK, calcium, Wnt, and Notch signaling. This integration suggests that astrocytomas achieve a state of robust proliferation and invasiveness by establishing feedback loops and cross-regulatory networks that ensure coordinated responses to multiple microenvironmental signals.\n\nOne particularly interesting aspect of this integration is the role of **IQGAP2** (IQGAP scaffolding protein 2, related to IQGAP1 referenced in search results[56]). IQGAP proteins serve as molecular scaffolds for calcium-dependent kinases, Rho GTPases, adhesion molecules, and signaling kinases, thereby enabling rapid integration of diverse signals into coordinated cellular responses. The presence of IQGAP2 in the gene list suggests that astrocytoma cells exploit IQGAP scaffolding to couple growth factor signals (activating IQGAP through direct phosphorylation) with cytoskeletal responses (through Rac/Rho modulation) and calcium-dependent transcriptional responses (through CAMK2 recruitment).\n\n## Specialized Functions and Context-Dependent Roles\n\nSeveral genes in the list encode proteins with highly specialized functions that, while not forming major pathways, nonetheless contribute important regulatory nodes. **HMGA2** (high mobility group AT-hook 2) is a chromatin-associated protein that promotes stemness and EMT in multiple cancer types, and its dysregulation in astrocytomas promotes maintenance of a progenitor-like state[46]. **HMGA2-AS1** is an antisense lncRNA that may regulate HMGA2 expression. **IGF2BP2** and **IGF2BP3** encode insulin-like growth factor 2 mRNA-binding proteins; these proteins regulate the stability and localization of mRNAs encoding growth factors and oncogenic proteins, thereby promoting tumor growth[46]. **L3MBTL4** encodes a polycomb-like protein involved in chromatin repression and may suppress differentiation genes.\n\n**VMP1** (vacuole membrane protein 1) is a lipid scramblase involved in autophagy and apoptosis; its dysregulation in astrocytomas may alter the balance between survival and death pathways. **LYST** (lysosomal trafficking regulator) regulates lysosomal trafficking and immune cell function, and its dysregulation could impact tumor cell interactions with immune infiltrates. **DPY19L1** and related dpy-19-like proteins regulate protein N-glycosylation, which critically influences cell adhesion, growth factor receptor signaling, and immune evasion. Together, these specialized genes contribute context-dependent regulatory functions that, while not forming major pathways themselves, nonetheless contribute to the overall tumor phenotype.\n\n## Clinical and Therapeutic Implications\n\nThe comprehensive analysis of these twelve gene programs reveals multiple targetable nodes and suggests strategies for therapeutic intervention. Foremost among these are the RTK signaling pathways, particularly FGFR1 and ALK, which are already the focus of clinical trials in astrocytoma subtypes harboring activating alterations. However, the identification of extensive negative regulatory networks (SPRY genes, DUSP6) highlights the importance of understanding why inhibitors of these pathways often fail or exhibit limited durability: bypass mechanisms through MAPK or PI3K pathway reactivation are likely driven by loss of negative regulators or activation of compensatory pathways.\n\nThe calcium signaling program is particularly intriguing from a therapeutic perspective. The reactivation of ionotropic glutamate receptors (GRIN2B, GRIA3, GRIK2) in astrocytomas suggests that these tumors may be susceptible to selective modulation of these channels. Indeed, recent preclinical work has demonstrated that NMDA receptor antagonists can suppress glioma growth, particularly in models with elevated GRIN2B expression. Similarly, modulation of the semaphorin-guided migration program through Plexin inhibitors or TRIO antagonists could suppress invasion and improve surgical extent of resection.\n\nThe metabolic reprogramming program offers opportunities for nutrient-based or metabolic enzyme-targeted therapies. BCAT1 has emerged as a particularly attractive therapeutic target, and both BCAT1 inhibitors and glutamine/leucine-restricting diets are under investigation in glioma models. The integration of metabolic reprogramming with hypoxia response suggests that combination therapies targeting both HIF and metabolic enzymes may achieve synergistic effects.\n\nFinally, the identification of extensive non-coding RNA dysregulation suggests that approaches targeting lncRNA stability or function (such as antisense oligonucleotides or siRNAs) may offer novel therapeutic modalities. The ceRNA function of lncRNAs (acting as \"sponges\" for miRNAs) suggests that restoring miRNA function through antagonism of tumor-promoting lncRNAs could suppress astrocytoma growth.\n\n## Conclusion\n\nThe comprehensive analysis of 169 genes in the context of astrocytoma biology reveals a complex, multi-layered regulatory architecture in which normal developmental and physiological programs are dysregulated to promote tumorigenesis and progression. Rather than simple activation of single oncogenic pathways, astrocytomas employ sophisticated integration of growth factor, calcium, metabolic, and developmental signaling networks to achieve a state of robust proliferation, enhanced invasiveness, and remarkable therapeutic resilience. The twelve identified gene programs—encompassing adhesion and cytoskeletal reorganization, growth factor receptor dynamics, calcium-mediated differentiation control, semaphorin-guided migration, developmental transcriptional networks, ECM remodeling, metabolic reprogramming, ion channel regulation, paracrine communication, Wnt/Notch integration, RNA processing, and specialized regulatory functions—collectively explain how astrocytoma cells achieve the cardinal hallmarks of cancer while maintaining some features of their astrocytic and neural lineage origins. The significant clustering of genes within each program, combined with extensive integration between programs, suggests that future therapeutic strategies should target not individual genes but rather entire programs or key nodes that coordinate multiple pathways. Moreover, the striking enrichment of genes regulating developmental processes and neural differentiation highlights the fundamental truth that astrocytomas are developmental diseases, wherein the normal programs guiding neural progenitor proliferation, migration, and differentiation are uncoupled from their growth-suppressive effects and redirected toward tumorigenesis.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"version\": \"1.0\",\n  \"context\": {\n    \"cell_type\": \"Astrocyte\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain\"\n  },\n  \"input_genes\": [\n    \"CAMK2D\",\n    \"MIR4435-2HG\",\n    \"CDK6\",\n    \"CYTOR\",\n    \"CHRM3\",\n    \"RGS6\",\n    \"KIAA1211L\",\n    \"KLHL4\",\n    \"CDH2\",\n    \"HIVEP3\",\n    \"SPRY4\",\n    \"TRIO\",\n    \"ADAMTS9\",\n    \"WWTR1\",\n    \"SPRED2\",\n    \"VAV3\",\n    \"PLAT\",\n    \"SATB2\",\n    \"CHRM3-AS2\",\n    \"SIPA1L1\",\n    \"GAP43\",\n    \"KCNIP1\",\n    \"PCNX2\",\n    \"GRIA3\",\n    \"ILDR2\",\n    \"IL1RAP\",\n    \"AC092691.1\",\n    \"CPNE4\",\n    \"IQGAP2\",\n    \"BCAT1\",\n    \"TRIM9\",\n    \"LRATD1\",\n    \"NOVA1\",\n    \"METTL7B\",\n    \"JAG1\",\n    \"DENND2A\",\n    \"PALM2-AKAP2\",\n    \"SPRED1\",\n    \"NRCAM\",\n    \"FREM2\",\n    \"DPF3\",\n    \"SPATA6\",\n    \"CNKSR2\",\n    \"HS2ST1\",\n    \"TNFRSF12A\",\n    \"GLDC\",\n    \"MYO16\",\n    \"CHL1\",\n    \"CDK14\",\n    \"CDH4\",\n    \"NEK6\",\n    \"STK17A\",\n    \"STK32A\",\n    \"STK32B\",\n    \"MED12L\",\n    \"CAMK2B\",\n    \"ARHGEF26\",\n    \"ARSJ\",\n    \"C6ORF141\",\n    \"GALR1\",\n    \"PTPRZ1\",\n    \"SH3PXD2B\",\n    \"RHOJ\",\n    \"SHROOM3\",\n    \"ITGB8\",\n    \"CREB5\",\n    \"AC092958.1\",\n    \"INSYN2A\",\n    \"LYST\",\n    \"CSMD2\",\n    \"ITGA3\",\n    \"ITGA7\",\n    \"KLHL29\",\n    \"AC124254.2\",\n    \"DPP6\",\n    \"KANK1\",\n    \"ZDHHC14\",\n    \"PREX1\",\n    \"P2RY14\",\n    \"AC004828.2\",\n    \"SLC35F1\",\n    \"CPNE8\",\n    \"TANC1\",\n    \"IGF2BP2\",\n    \"EML4\",\n    \"ADAM19\",\n    \"COL22A1\",\n    \"ACSS3\",\n    \"SRPX\",\n    \"FRMD5\",\n    \"MEIS1\",\n    \"ESR2\",\n    \"SEMA5A\",\n    \"ENC1\",\n    \"SYNJ2\",\n    \"COL4A2\",\n    \"MEG8\",\n    \"SEMA3E\",\n    \"MAP3K1\",\n    \"POSTN\",\n    \"DLC1\",\n    \"DNMBP\",\n    \"ETV5\",\n    \"DEC1\",\n    \"ABCC3\",\n    \"LONRF2\",\n    \"CEMIP\",\n    \"LINC02742\",\n    \"SHISA9\",\n    \"ETV6\",\n    \"MAMLD1\",\n    \"ERI1\",\n    \"FGF14\",\n    \"SNTG1\",\n    \"FNDC3B\",\n    \"CLMN\",\n    \"SPRY2\",\n    \"PRAG1\",\n    \"SLC8A1\",\n    \"LSAMP\",\n    \"LMO2\",\n    \"DNM1\",\n    \"PDE8A\",\n    \"AC087564.1\",\n    \"GRIK2\",\n    \"RCAN1\",\n    \"GRIN2B\",\n    \"ALK\",\n    \"VMP1\",\n    \"AL356124.1\",\n    \"LEF1\",\n    \"HMGA2\",\n    \"HMGA2-AS1\",\n    \"LDLRAD3\",\n    \"IGF2BP3\",\n    \"PCDH7\",\n    \"LAMC1\",\n    \"PCDH9-AS2\",\n    \"TRPM3\",\n    \"ACSBG1\",\n    \"NES\",\n    \"ADGRL3\",\n    \"ADAM12\",\n    \"HS3ST5\",\n    \"ADAMTS9-AS1\",\n    \"MTCL1\",\n    \"UBASH3B\",\n    \"ARHGAP26\",\n    \"RASSF8\",\n    \"AC017002.5\",\n    \"PGAP1\",\n    \"LIMK1\",\n    \"RYR3\",\n    \"AC060834.2\",\n    \"ZMAT4\",\n    \"KCNMA1\",\n    \"SCD5\",\n    \"SAMD4A\",\n    \"RUNX1\",\n    \"NPAS3\",\n    \"AC064875.1\",\n    \"SCG2\",\n    \"GAS2\",\n    \"OSBP2\",\n    \"PDGFA\",\n    \"LAMA4\",\n    \"SLC35F4\",\n    \"EMP1\",\n    \"KCND2\",\n    \"DPYSL5\",\n    \"RFFL\",\n    \"KALRN\",\n    \"ITPR2\",\n    \"LAMA2\",\n    \"SLC1A2\",\n    \"ELOVL2\",\n    \"L3MBTL4\",\n    \"DPY19L1\",\n    \"RBPMS\",\n    \"RGS17\",\n    \"LPAR1\",\n    \"DUSP6\",\n    \"LINC01138\",\n    \"RNF157\",\n    \"PXYLP1\",\n    \"LHFPL6\",\n    \"FBN2\",\n    \"RUBCNL\",\n    \"FGFR1\",\n    \"SH3KBP1\",\n    \"GRB10\",\n    \"GPR158\",\n    \"LINC01798\",\n    \"EPHA3\",\n    \"PTPRJ\",\n    \"GNG12-AS1\",\n    \"PRKD1\",\n    \"PVT1\",\n    \"LINC00266-1\",\n    \"SEMA3A\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Cellular Adhesion and Cytoskeletal Reorganization\",\n      \"description\": \"Coordinated regulation of cell-cell adhesion through cadherins (CDH2, CDH4) and integrin-based focal adhesion complexes (ITGB8, ITGA3, ITGA7), coupled with extensive remodeling of the actin cytoskeleton through Rho family GTPases (RHOJ, VAV3, ARHGEF26, ARHGAP26) and their effectors (LIMK1, KALRN, SHROOM3). This program enables the morphological plasticity required for astrocytoma invasion and therapeutic resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Adherens junction assembly and disassembly\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Cadherins regulate astrocyte morphology and are dynamically remodeled in response to injury and tumor progression\"\n            },\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"CDH2 and related cadherins control cell polarity and EMT-like transitions in cancer contexts\"\n            }\n          ],\n          \"genes\": [\n            \"CDH2\",\n            \"CDH4\",\n            \"NRCAM\"\n          ]\n        },\n        {\n          \"name\": \"Integrin-mediated focal adhesion signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Integrin alpha and beta subunits orchestrate focal adhesion formation and mechanotransduction\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"ILK recruits focal adhesion adaptors PINCH and Parvin to establish heterotrimeric complexes triggering F-actin bundling\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Pericytes in glioma establish integrin-dependent interactions with extracellular matrix\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB8\",\n            \"ITGA3\",\n            \"ITGA7\",\n            \"ARHGEF26\"\n          ]\n        },\n        {\n          \"name\": \"Rho GTPase-dependent actin polymerization and cytoskeletal remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"RhoJ inactivation promotes actin polymerization and cell motility through PAK1-dependent signaling\"\n            },\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"CDC42 and RhoJ coordinate filopodial dynamics and actin polymerization at cell migration fronts\"\n            },\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"TRIO and CRMP2 regulate axon branching through coordination of Rho GTPase activity\"\n            }\n          ],\n          \"genes\": [\n            \"RHOJ\",\n            \"VAV3\",\n            \"LIMK1\",\n            \"SHROOM3\",\n            \"KALRN\",\n            \"ARHGAP26\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Adherens junctions and N-cadherin complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"N-cadherin-mediated adherens junctions are critical for neural tissue integrity and dynamically remodeled in astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"CDH2\",\n            \"CDH4\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Focal adhesions are multimeric protein complexes linking integrins to the actin cytoskeleton through adaptor proteins\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Pericytes maintain strategic positioning adjacent to blood vessels through integrin-dependent focal adhesions\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB8\",\n            \"ITGA3\",\n            \"ITGA7\",\n            \"ARHGEF26\",\n            \"LIMK1\"\n          ]\n        },\n        {\n          \"name\": \"F-actin bundles and stress fibers\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"F-actin organization at the tips of filopodia and stress fibers governs cell morphology and migration\"\n            },\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"Actin dynamics control cellular polarity and regulate expression of genes involved in EMT and migration\"\n            }\n          ],\n          \"genes\": [\n            \"LIMK1\",\n            \"SHROOM3\",\n            \"KALRN\",\n            \"RHOJ\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell-cell detachment and reduced contact inhibition via altered cadherin expression\",\n        \"Increased filopodial dynamics and membrane blebbing promoting migration and invasion\",\n        \"Amplified mechanotransduction signals from integrin-ECM interactions governing proliferation and survival\",\n        \"Remodeling of cell shape from stellate (ramified) to rounded or spindle-like morphologies facilitating infiltration\",\n        \"Dysregulated coupling between adhesion and growth factor signaling enabling Rho-mediated MAPK pathway activation\"\n      ],\n      \"evidence_summary\": \"Eight genes in the input list encode core components of adherens junctions (CDH2, CDH4, NRCAM) and integrin focal adhesions (ITGB8, ITGA3, ITGA7, ARHGEF26), while six genes encode regulators of Rho GTPase signaling and actin dynamics (RHOJ, VAV3, LIMK1, SHROOM3, KALRN, ARHGAP26). The concentration of these factors in a single program, combined with their known roles in coordinating cell-cell contact and cytoskeletal remodeling, indicates this is a core hallmark of astrocytoma pathogenesis. Literature demonstrates that dysregulation of cadherins promotes EMT-like transitions and invasion, while altered Rho signaling correlates with migration and therapeutic resistance. The presence of both positive regulators (GEFs) and negative regulators (GAPs) suggests dynamic on-off switching of adhesion and migration programs.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"ITGB8 integrin beta subunit establishes integrin-mediated focal adhesion signaling\"\n        },\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"ILK recruits focal adhesion adaptors PINCH and Parvin into heterotrimeric complexes\"\n        },\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"Pericytes maintain strategic positioning adjacent to blood vessels with integrin-dependent interactions\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Astrocyte morphology and adhesion dynamically change following injury with altered GFAP and NRCAM expression\"\n        },\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"RhoJ inactivation promotes actin polymerization and cell motility\"\n        },\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"CDC42 promotes cell migration and actin polymerization at growth cone tips\"\n        },\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Trio and CRMP2 regulate axon branching through coordination of Rho GTPase activity\"\n        },\n        {\n          \"source_id\": \"57\",\n          \"notes\": \"Wnt signaling drives cytoarchitectural changes and EMT-like transitions affecting actin and cadherin dynamics\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CDH2\",\n        \"CDH4\",\n        \"ITGB8\",\n        \"ITGA3\",\n        \"ITGA7\",\n        \"NRCAM\",\n        \"RHOJ\",\n        \"VAV3\",\n        \"LIMK1\",\n        \"SHROOM3\",\n        \"KALRN\",\n        \"ARHGEF26\",\n        \"ARHGAP26\",\n        \"PCDH7\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CDK5\",\n          \"APC\",\n          \"AXIN1\",\n          \"GSK3B\",\n          \"COFILIN\",\n          \"MLC\",\n          \"ROCK1\",\n          \"PAK1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"37\",\n            \"notes\": \"PAK1 is a key effector of Rac/Rho signaling in growth cone regulation\"\n          },\n          {\n            \"source_id\": \"36\",\n            \"notes\": \"ROCK1 acts downstream of Rho to phosphorylate and stabilize actin filaments\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Growth Factor Receptor Signaling and Pathway Dynamics\",\n      \"description\": \"Dysregulation of receptor tyrosine kinase signaling through FGFR1, PDGFA, and ALK, integrated with extensive negative feedback regulation via SPRY/SPRED family members (SPRY2, SPRY4, SPRED1, SPRED2) and phosphatase DUSP6. This program enables sustained activation of MAPK and PI3K/AKT cascades driving proliferation and survival, while dysregulation of negative regulators permits bypass of therapeutic RTK inhibitors.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Receptor tyrosine kinase activation and autophosphorylation\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"FGFR1 and PDGFRA are frequently amplified or fused in pediatric gliomas driving constitutive MAPK activation\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"PDGFRA and EGFRvIII require co-signaling for full transforming capacity in glioblastoma\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"FGFR2 amplification activates both FGFR and EGFR signaling pathways for cell proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"FGFR1\",\n            \"PDGFA\",\n            \"ALK\",\n            \"FGF14\"\n          ]\n        },\n        {\n          \"name\": \"Negative feedback regulation of RTK signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"DUSP6 dephosphorylates ERK1/2 and is frequently downregulated in gliomas permitting sustained MAPK activation\"\n            },\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"SPRY and SPRED families act as molecular brakes on growth factor signaling through multiple mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"SPRY2\",\n            \"SPRY4\",\n            \"SPRED1\",\n            \"SPRED2\",\n            \"DUSP6\"\n          ]\n        },\n        {\n          \"name\": \"MAPK pathway activation and ERK phosphorylation\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"TRIM24::NTRK2 fusion drives sustained MAPK pathway activation with elevated pERK levels over serial surgeries\"\n            },\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"KIAA1549::BRAF and BRAFV600E mutations drive MAPK pathway activation in pediatric low-grade gliomas\"\n            }\n          ],\n          \"genes\": [\n            \"PRKD1\",\n            \"CREB5\",\n            \"ETV5\",\n            \"ETV6\"\n          ]\n        },\n        {\n          \"name\": \"RTK signaling via scaffolding and adaptor proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"IQGAP1 promotes cancer cell motility through Rac1-dependent signaling and FAK activation\"\n            }\n          ],\n          \"genes\": [\n            \"IQGAP2\",\n            \"TRIM9\",\n            \"GRB10\",\n            \"SH3KBP1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Receptor tyrosine kinase complexes at the plasma membrane\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"FGFR1 and PDGFRA receptors form ligand-induced dimers triggering autophosphorylation\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"PDGFRA and other RTKs form multi-subunit signaling complexes with kinase substrates\"\n            }\n          ],\n          \"genes\": [\n            \"FGFR1\",\n            \"PDGFA\",\n            \"ALK\"\n          ]\n        },\n        {\n          \"name\": \"MAPK signaling cascade complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"MAPK1 (ERK2) is an integration point for multiple upstream kinase cascades controlling proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"PRKD1\",\n            \"CREB5\",\n            \"ETV5\",\n            \"ETV6\"\n          ]\n        },\n        {\n          \"name\": \"Endosomal RTK recycling and degradation complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"TRIM24 fusion protein regulates RTK trafficking and persistence of oncogenic signaling\"\n            }\n          ],\n          \"genes\": [\n            \"TRIM9\",\n            \"DENND2A\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Sustained MAPK (ERK1/2) phosphorylation driving proliferation and expression of stem-like genes\",\n        \"Amplified PI3K/AKT signaling promoting cell survival and metabolic reprogramming\",\n        \"Loss of negative feedback allowing RTK signaling to persist despite ligand removal or receptor internalization\",\n        \"Activation of ETS transcription factors promoting expression of genes supporting progenitor identity and reduced differentiation\",\n        \"Cross-talk between RTK and integrin signaling amplifying invasive and migratory phenotypes\"\n      ],\n      \"evidence_summary\": \"Four RTK genes (FGFR1, PDGFA, ALK, FGF14) are present in the input list alongside five negative regulators (SPRY2, SPRY4, SPRED1, SPRED2, DUSP6) and multiple downstream effectors (PRKD1, CREB5, ETV5, ETV6, IQGAP2, TRIM9, GRB10, SH3KBP1). The coordinated presence of positive and negative regulators is particularly significant, as astrocytomas frequently exhibit loss of expression or function of SPRY/SPRED genes, creating an imbalance toward sustained RTK signaling. Literature documents that FGFR1 amplification is common in pediatric gliomas, while loss of SPRY genes correlates with reduced survival. The presence of multiple downstream effectors suggests complex integration of RTK signals with other pathways.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"TRIM24::NTRK2 fusion drives oncogenic MAPK pathway activation\"\n        },\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"FGFR1, PDGFRA, and BRAF alterations drive MAPK pathway activation in pediatric gliomas\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"PDGFRA and EGFR co-signaling required for glioblastoma transformation\"\n        },\n        {\n          \"source_id\": \"18\",\n          \"notes\": \"FGFR2 amplification drives MAPK and EGFR pathway activation in gastric cancer\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"DUSP6 downregulation in astrocytes permits sustained MAPK activation\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"SPRY and SPRED genes act as negative regulators of RTK signaling\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"IQGAP1 scaffolds Rac1 signaling downstream of growth factor receptors\"\n        },\n        {\n          \"source_id\": \"58\",\n          \"notes\": \"MAPK1 integrates multiple upstream kinase cascades\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"FGFR1\",\n        \"PDGFA\",\n        \"ALK\",\n        \"FGF14\",\n        \"SPRY2\",\n        \"SPRY4\",\n        \"SPRED1\",\n        \"SPRED2\",\n        \"DUSP6\",\n        \"PRKD1\",\n        \"CREB5\",\n        \"ETV5\",\n        \"ETV6\",\n        \"IQGAP2\",\n        \"TRIM9\",\n        \"GRB10\",\n        \"SH3KBP1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EGFR\",\n          \"PDGFRB\",\n          \"ERK1\",\n          \"ERK2\",\n          \"RAF1\",\n          \"MEK1\",\n          \"MEK2\",\n          \"PI3K\",\n          \"AKT1\",\n          \"AKT2\",\n          \"GAB1\",\n          \"GAB2\",\n          \"SOS1\",\n          \"GRB2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"ERK phosphorylation downstream of RTK signaling indicates MAPK cascade activation\"\n          },\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"BRAF drives MEK/ERK pathway activation in pilocytic astrocytomas\"\n          },\n          {\n            \"source_id\": \"18\",\n            \"notes\": \"EGFR pathway activation occurs alongside FGFR2 signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Calcium Signaling and Differentiation Control\",\n      \"description\": \"Dysregulation of calcium homeostasis through ionotropic glutamate receptors (GRIN2B, GRIA3, GRIK2), voltage-gated cation channels (TRPM3, SLC8A1), and intracellular calcium release channels (ITPR2, RYR3). Coordinated with calcium-responsive kinases (CAMK2D, CAMK2B) and developmental transcription factors (NOVA1, RBPMS), this program links developmental differentiation machinery to calcium-dependent proliferation and stemness.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Ionotropic glutamate receptor-mediated calcium influx\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"GRIN2A encodes an NMDA receptor subunit enabling glutamate-gated calcium entry\"\n            },\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"GRIN2B expression is increased in schizophrenia-associated models and influences calcium dynamics\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN2B\",\n            \"GRIA3\",\n            \"GRIK2\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated cation channel-mediated calcium entry\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"Ion channels regulate calcium entry and electrical properties of neural cells\"\n            }\n          ],\n          \"genes\": [\n            \"TRPM3\",\n            \"SLC8A1\",\n            \"KCNMA1\",\n            \"KCND2\",\n            \"KCNIP1\"\n          ]\n        },\n        {\n          \"name\": \"Intracellular calcium mobilization and store release\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"ITPR2 and RYR3 mediate calcium release from endoplasmic reticulum stores\"\n            }\n          ],\n          \"genes\": [\n            \"ITPR2\",\n            \"RYR3\"\n          ]\n        },\n        {\n          \"name\": \"Calcium-calmodulin dependent kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"CAMK2 integrates calcium signals to drive transcriptional programs\"\n            },\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"Calcium-responsive kinases including CAMKs drive differentiation and proliferation programs\"\n            }\n          ],\n          \"genes\": [\n            \"CAMK2D\",\n            \"CAMK2B\",\n            \"PRKD1\"\n          ]\n        },\n        {\n          \"name\": \"Calcium-dependent transcriptional and splicing programs\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"NOVA1 and RBPMS regulate calcium-dependent alternative splicing of neural genes\"\n            }\n          ],\n          \"genes\": [\n            \"NOVA1\",\n            \"RBPMS\",\n            \"CREB5\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"NMDA and AMPA receptor complexes at the plasma membrane\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"GRIN2B and GRIA subunits form ligand-gated ion channel complexes\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN2B\",\n            \"GRIA3\",\n            \"GRIK2\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated cation channel complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"TRPM3, KCNMA1, and related channels form multimeric complexes regulating ion flow\"\n            }\n          ],\n          \"genes\": [\n            \"TRPM3\",\n            \"KCNMA1\",\n            \"KCND2\",\n            \"KCNIP1\"\n          ]\n        },\n        {\n          \"name\": \"Endoplasmic reticulum calcium release channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"ITPR2 and RYR3 are ER-resident channels mediating IP3 and ryanodine-sensitive calcium release\"\n            }\n          ],\n          \"genes\": [\n            \"ITPR2\",\n            \"RYR3\"\n          ]\n        },\n        {\n          \"name\": \"Calmodulin-dependent kinase complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"CAMK2 forms multimeric complexes with calmodulin and substrate proteins\"\n            }\n          ],\n          \"genes\": [\n            \"CAMK2D\",\n            \"CAMK2B\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Elevated intracellular calcium concentration driving transcriptional programs normally active in immature neural progenitors\",\n        \"Ectopic expression of neuronal calcium signaling machinery in tumor astrocytes creating developmentally inappropriate responses\",\n        \"Activation of calcium-CAMK-dependent CREB signaling promoting proliferation rather than differentiation\",\n        \"Altered calcium oscillation dynamics affecting the balance between proliferation and migration\",\n        \"Reactivation of developmental neurite outgrowth programs (KALRN, GAP43) through calcium-dependent signaling\"\n      ],\n      \"evidence_summary\": \"Six genes encoding ionotropic glutamate receptors and calcium-permeable channels (GRIN2B, GRIA3, GRIK2, TRPM3, SLC8A1, ITPR2, RYR3) are present, integrated with four calcium-responsive kinases and transcription factors (CAMK2D, CAMK2B, PRKD1, CREB5) and two calcium-dependent RNA-binding proteins (NOVA1, RBPMS). The presence of ionotropic glutamate receptors in astrocytomas is particularly significant, as mature astrocytes express these receptors at very low levels. Combined with calcium-dependent kinases and developmental transcription factors, this program reveals that astrocytomas reactivate developmental differentiation machinery in a pathological manner. Calcium signaling is known to be critical for neural progenitor proliferation and differentiation decisions, and its dysregulation in tumors uncouples differentiation cues from growth suppression.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"GRIN2A and ion channels regulate neural cell calcium dynamics\"\n        },\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"GRIN2B expression and CAMK2 signaling altered in neural disease models\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Astrocyte gene expression alterations include calcium-related genes (Grin3a, Gria2)\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"Calcium and ion homeostasis genes (Grin3a, Gria2, Slc1a3) are downregulated post-TBI\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"NOVA1 and RNA-binding proteins regulate calcium-dependent splicing in neural development\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"ITPR2 and RYR3 regulate calcium oscillations driving differentiation programs\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GRIN2B\",\n        \"GRIA3\",\n        \"GRIK2\",\n        \"TRPM3\",\n        \"SLC8A1\",\n        \"ITPR2\",\n        \"RYR3\",\n        \"KCNMA1\",\n        \"KCND2\",\n        \"KCNIP1\",\n        \"CAMK2D\",\n        \"CAMK2B\",\n        \"PRKD1\",\n        \"CREB5\",\n        \"NOVA1\",\n        \"RBPMS\",\n        \"KALRN\",\n        \"GAP43\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CALMODULIN\",\n          \"CAMK1\",\n          \"CAMK4\",\n          \"CaMKIV\",\n          \"RCAN1\",\n          \"DYRK1A\",\n          \"CALCINEURIN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"25\",\n            \"notes\": \"RCAN1 is involved in calcium-dependent signaling and neuroprotection\"\n          },\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"Calmodulin and calcineurin are critical regulators of calcium-dependent neural progenitor differentiation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Semaphorin-Guided Cell Migration and Axon Guidance\",\n      \"description\": \"Reactivation of developmental axon guidance machinery, including secreted semaphorins (SEMA3A, SEMA5A, SEMA3E), semaphorin receptor-associated signaling proteins (TRIO, CRMP2-related pathways), and downstream cytoskeletal regulators (LIMK1, RHOJ). This program exploits normal neuronal guidance cues to orchestrate tumor cell invasion along neural tissue tracts and promotes dynamic filopodial dynamics.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Semaphorin ligand production and secretion\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Sema3A is a well-known repulsive axon guidance cue triggering growth cone collapse\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"SEMA3C protein levels correlate with glioma progression and serve as prognostic marker\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA3A\",\n            \"SEMA5A\",\n            \"SEMA3E\"\n          ]\n        },\n        {\n          \"name\": \"Semaphorin-plexin signaling and growth cone response\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Sema3A signaling recruits Trio and phosphorylated CRMP2 to suppress filopodial motility\"\n            }\n          ],\n          \"genes\": [\n            \"TRIO\",\n            \"LIMK1\",\n            \"RHOJ\"\n          ]\n        },\n        {\n          \"name\": \"Filopodial dynamics and membrane protrusions\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"RhoJ inactivation promotes actin polymerization at filopodial tips\"\n            },\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Trio suppresses filopodial motility when complexed with phosphorylated CRMP2\"\n            }\n          ],\n          \"genes\": [\n            \"RHOJ\",\n            \"TRIO\",\n            \"LIMK1\"\n          ]\n        },\n        {\n          \"name\": \"Cofilin phosphorylation and actin filament stabilization\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"LIMK1 phosphorylates cofilin downstream of semaphorin signaling to stabilize F-actin\"\n            }\n          ],\n          \"genes\": [\n            \"LIMK1\",\n            \"KALRN\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Secreted semaphorin ligands\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Sema3A is a secreted semaphorin with repulsive axon guidance function\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA3A\",\n            \"SEMA5A\",\n            \"SEMA3E\"\n          ]\n        },\n        {\n          \"name\": \"Semaphorin receptor and effector complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"TRIO interacts with CRMP2 in the growth cone fraction during Sema3A signaling\"\n            }\n          ],\n          \"genes\": [\n            \"TRIO\"\n          ]\n        },\n        {\n          \"name\": \"Filopodial actin filaments\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Filopodial structure depends on dynamic actin polymerization regulated by Rho GTPases\"\n            },\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"CDC42 and RhoJ regulate actin polymerization at filopodial tips\"\n            }\n          ],\n          \"genes\": [\n            \"RHOJ\",\n            \"LIMK1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Exploitation of developmental semaphorin guidance cues to direct tumor cell invasion along white matter tracts\",\n        \"Dynamic switching between motile (filopodial) and non-motile (collapsed) states in response to guidance cues\",\n        \"Potential creation of invasive pseudopodia mimicking neuronal growth cones\",\n        \"Integration of guidance signaling with growth factor pathways to coordinate migration with proliferation\",\n        \"Aberrant activation of developmental programs that normally guide neural progenitor migration during neurogenesis\"\n      ],\n      \"evidence_summary\": \"Three semaphorin genes (SEMA3A, SEMA5A, SEMA3E) are present alongside key mediators of semaphorin signaling (TRIO, LIMK1, RHOJ). Notably, TRIO interacts with phosphorylated CRMP2 to suppress filopodial dynamics downstream of semaphorin signaling, and its dysregulation in astrocytomas could result in uncontrolled migration or pathological locking of cells in non-migratory states. The concentration of semaphorin-related genes is striking given that semaphorins and their receptors are classically associated with developmental axon guidance, not cancer. However, recent literature demonstrates that multiple cancer types hijack this machinery for invasion and metastasis, and astrocytomas may similarly exploit developmental guidance cues by expressing both ligands and receptors.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"Tumor cells exploit developmental cues for invasion and metastasis\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Astrocyte-derived progenitors express markers of neural differentiation and migration\"\n        },\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Trio and CRMP2 regulate axon branching through semaphorin signaling\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"SEMA3C levels correlate with glioma progression and prognosis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SEMA3A\",\n        \"SEMA5A\",\n        \"SEMA3E\",\n        \"TRIO\",\n        \"LIMK1\",\n        \"RHOJ\",\n        \"KALRN\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"NRP1\",\n          \"NRP2\",\n          \"PLXNA1\",\n          \"PLXNA2\",\n          \"PLXNA3\",\n          \"PLXNA4\",\n          \"CRMP2\",\n          \"PAK1\",\n          \"ROCK1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"37\",\n            \"notes\": \"Neuropilins and plexins are semaphorin receptors required for signaling\"\n          },\n          {\n            \"source_id\": \"37\",\n            \"notes\": \"CRMP2 phosphorylation is essential for semaphorin-induced growth cone collapse\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neural Differentiation Markers and Developmental Transcriptional Networks\",\n      \"description\": \"Reactivation of neural progenitor differentiation transcriptional programs through coordinated action of transcription factors (SATB2, LEF1, RUNX1, CREB5, ETV5, ETV6) and developmental markers (GAP43, SNTG1, LSAMP, LMO2). These factors drive expression of genes associated with neural differentiation and stemness while simultaneously uncoupling differentiation from growth suppression, creating a distinctive tumor phenotype.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transcriptional regulation of neural lineage specification\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"SATB2 regulates neural lineage commitment and neuronal versus oligodendroglial fates\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"RUNX1 cooperates with LEF1 in hematopoietic and neural differentiation\"\n            }\n          ],\n          \"genes\": [\n            \"SATB2\",\n            \"LEF1\",\n            \"RUNX1\"\n          ]\n        },\n        {\n          \"name\": \"Wnt signaling pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"Wnt3A and LEF1 drive canonical Wnt signaling promoting stemness\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"CTNNBIP1 and LEF1 regulate Wnt/beta-catenin signaling and stemness\"\n            }\n          ],\n          \"genes\": [\n            \"LEF1\",\n            \"RUNX1\",\n            \"CREB5\"\n          ]\n        },\n        {\n          \"name\": \"MAPK-dependent ETS transcription factor activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"ETS family transcription factors are direct targets of MAPK signaling\"\n            }\n          ],\n          \"genes\": [\n            \"ETV5\",\n            \"ETV6\"\n          ]\n        },\n        {\n          \"name\": \"Expression of neural differentiation markers\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"GAP43 and neural progenitor markers are expressed in astrocyte-derived cells\"\n            }\n          ],\n          \"genes\": [\n            \"GAP43\",\n            \"SNTG1\",\n            \"LSAMP\",\n            \"LMO2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factor complexes regulating neural genes\",\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"RUNX1 forms complexes with LEF1 and other factors to control neural development genes\"\n            }\n          ],\n          \"genes\": [\n            \"SATB2\",\n            \"LEF1\",\n            \"RUNX1\",\n            \"CREB5\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin remodeling complexes at developmental loci\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"BAF chromatin remodeling complexes regulate access to developmentally regulated genes\"\n            }\n          ],\n          \"genes\": [\n            \"DPF3\",\n            \"SATB2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Sustained expression of neural progenitor identity genes promoting proliferation rather than terminal differentiation\",\n        \"Aberrant reactivation of Wnt signaling driving stemness and reduced differentiation\",\n        \"MAPK-dependent ETS factor activation promoting expression of plasticity genes\",\n        \"Ectopic neuronal marker expression (GAP43, SNTG1) in tumor cells creating hybrid phenotypes\",\n        \"Dysregulation of developmental fate-determination mechanisms allowing simultaneous expression of conflicting lineage programs\"\n      ],\n      \"evidence_summary\": \"Seven transcription factor genes (SATB2, LEF1, RUNX1, CREB5, ETV5, ETV6, DPF3) combine with four neural differentiation marker genes (GAP43, SNTG1, LSAMP, LMO2) to establish a developmental transcriptional program. The presence of master regulators of neural differentiation (SATB2, LEF1, RUNX1) alongside MAPK-responsive factors (ETV5, ETV6) suggests that astrocytomas integrate developmental and growth factor signals to maintain a state of simultaneous differentiation and proliferation. This is particularly relevant in pediatric astrocytomas, which frequently harbor MAPK pathway alterations (BRAF mutations, KIAA1549::BRAF fusions) and where early transcriptome analysis reveals activation of neural progenitor-associated genes.\",\n      \"significance_score\": 0.87,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"SATB2 and BRAF drive neural differentiation programs in pediatric gliomas\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"Astrocyte-derived progenitor cells express neural differentiation markers including GAP43\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"LEF1 and CTNNBIP1 regulate Wnt signaling and stemness\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"RUNX1 regulates hematopoietic and neural lineage differentiation\"\n        },\n        {\n          \"source_id\": \"58\",\n          \"notes\": \"ETV family transcription factors are downstream effectors of MAPK signaling\"\n        },\n        {\n          \"source_id\": \"59\",\n          \"notes\": \"Wnt signaling promotes stemness and prevents differentiation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SATB2\",\n        \"LEF1\",\n        \"RUNX1\",\n        \"CREB5\",\n        \"ETV5\",\n        \"ETV6\",\n        \"DPF3\",\n        \"GAP43\",\n        \"SNTG1\",\n        \"LSAMP\",\n        \"LMO2\",\n        \"HMGA2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"NEUROD1\",\n          \"NEUROGENIN\",\n          \"ASCL1\",\n          \"PAX6\",\n          \"EMX1\",\n          \"CTNNB1\",\n          \"TCF7\",\n          \"BRPF1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"ASCL1 drives neuronal differentiation from astrocytes in developmental contexts\"\n          },\n          {\n            \"source_id\": \"41\",\n            \"notes\": \"TCF7 and CTNNB1 form the canonical Wnt signaling complex\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling and Invasion\",\n      \"description\": \"Coordinated remodeling of the tumor microenvironment through secreted proteases (ADAMTS9, ADAM12, ADAM19) and structural ECM proteins (COL4A2, COL22A1, FBN2, POSTN, LAMC1, LAMA2, LAMA4). This program enables basement membrane degradation, ECM stroma remodeling, and vascular co-option while creating a permissive microenvironment for tumor cell infiltration.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Proteolytic basement membrane degradation\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"ADAMTS9 and related proteases cleave versican and other proteoglycans reducing ECM stability\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Basement membrane invasion occurs before meningeal spread and glioma metastasis\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS9\",\n            \"ADAM12\",\n            \"ADAM19\"\n          ]\n        },\n        {\n          \"name\": \"Collagen deposition and ECM remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Collagen types IV and XXII constitute basement membrane and dermis\"\n            }\n          ],\n          \"genes\": [\n            \"COL4A2\",\n            \"COL22A1\",\n            \"LAMC1\",\n            \"LAMA2\",\n            \"LAMA4\"\n          ]\n        },\n        {\n          \"name\": \"Matricellular protein and fibrotic remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Pericytes coordinate tumor and stromal cell interactions through ECM remodeling\"\n            }\n          ],\n          \"genes\": [\n            \"POSTN\",\n            \"FBN2\"\n          ]\n        },\n        {\n          \"name\": \"Angiogenesis-associated ECM changes\",\n          \"citations\": [\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"Host angiogenic reprogramming by pathogenic proteins involves PDGFR/PI3K/AKT/FAK signaling\"\n            }\n          ],\n          \"genes\": [\n            \"POSTN\",\n            \"ADAMTS9\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Secreted protease complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"ADAMTS proteases are secreted multimeric enzymes with thrombospondin domains\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS9\",\n            \"ADAM12\",\n            \"ADAM19\"\n          ]\n        },\n        {\n          \"name\": \"Type IV collagen and basement membrane components\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Type IV collagen forms the structural backbone of basement membrane\"\n            }\n          ],\n          \"genes\": [\n            \"COL4A2\",\n            \"LAMC1\"\n          ]\n        },\n        {\n          \"name\": \"Laminin heterotrimer complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Laminins comprise heterotrimeric matrix proteins anchoring basement membrane\"\n            }\n          ],\n          \"genes\": [\n            \"LAMA2\",\n            \"LAMA4\",\n            \"LAMC1\"\n          ]\n        },\n        {\n          \"name\": \"Matricellular and fibrillary proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Extracellular matrix and stroma support tumor vascularization and immune infiltration\"\n            }\n          ],\n          \"genes\": [\n            \"FBN2\",\n            \"POSTN\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced invasiveness through proteolytic breakdown of basement membrane barriers\",\n        \"Vascular co-option and angiogenic mimicry through ECM remodeling\",\n        \"Creation of a fibrotic desmoplastic microenvironment that suppresses immune infiltration\",\n        \"Altered mechanotransduction due to changes in ECM stiffness and composition\",\n        \"Facilitated metastatic potential through enhanced ECM degradation capacity\"\n      ],\n      \"evidence_summary\": \"Nine genes encoding proteases (ADAMTS9, ADAM12, ADAM19) and ECM structural proteins (COL4A2, COL22A1, FBN2, POSTN, LAMC1, LAMA2, LAMA4) are present, with the addition of ADAMTS9-AS1 (a lncRNA regulating ADAMTS9) suggesting multi-level control. The coordinated presence of both proteases that degrade ECM and ECM proteins that are subsequently remodeled suggests dynamic ECM turnover. Literature demonstrates that ADAMTS9 is upregulated in invasive gliomas and promotes invasion through proteolytic degradation of versican and other proteoglycans. The presence of multiple collagen and laminin genes alongside proteases suggests that astrocytomas simultaneously degrade existing ECM barriers while depositing new, tumor-supportive ECM.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"ADAMTS9 is a secreted protease cleaving versican and promoting invasiveness\"\n        },\n        {\n          \"source_id\": \"11\",\n          \"notes\": \"MMP14 (matrix metalloproteinase 14) is involved in ECM breakdown in physiological processes\"\n        },\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"Pericytes and tumor stroma interact through ECM-mediated signaling\"\n        },\n        {\n          \"source_id\": \"16\",\n          \"notes\": \"Basement membrane-related genes establish risk models in glioblastoma\"\n        },\n        {\n          \"source_id\": \"52\",\n          \"notes\": \"PDGF-BB and angiogenic factors drive pathological ECM remodeling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ADAMTS9\",\n        \"ADAM12\",\n        \"ADAM19\",\n        \"COL4A2\",\n        \"COL22A1\",\n        \"FBN2\",\n        \"POSTN\",\n        \"LAMC1\",\n        \"LAMA2\",\n        \"LAMA4\",\n        \"ADAMTS9-AS1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\",\n          \"MMP9\",\n          \"MMP14\",\n          \"TIMP1\",\n          \"TIMP2\",\n          \"TIMP3\",\n          \"TIMP4\",\n          \"NIDOGEN1\",\n          \"PERLECAN\",\n          \"AGGRECAN\",\n          \"VERSICAN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"ADAMTS proteases cleave versican and AGGRECAN\"\n          },\n          {\n            \"source_id\": \"11\",\n            \"notes\": \"MMP14 is involved in ECM remodeling\"\n          },\n          {\n            \"source_id\": \"16\",\n            \"notes\": \"Basement membrane components like NIDOGEN and PERLECAN are structural elements\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming Toward Amino Acid Anabolism\",\n      \"description\": \"Dysregulation of amino acid and lipid metabolism through enzymes (BCAT1, GLDC, ACSS3, SCD5, ELOVL2) supporting rapid biosynthesis and altered energy metabolism. Coupled with altered glutamate/glutamine homeostasis (SLC1A2), this program enables astrocytoma survival under hypoxic, nutrient-restricted conditions and supports rapid proliferation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Branched-chain amino acid catabolism and anaplerosis\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"BCAT1 elevation correlates with poor prognosis in glioblastomas through anaplerotic TCA cycle replenishment\"\n            }\n          ],\n          \"genes\": [\n            \"BCAT1\"\n          ]\n        },\n        {\n          \"name\": \"Glycine metabolism and one-carbon synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"Glycine metabolism and one-carbon pathways support nucleotide synthesis in neural cells\"\n            }\n          ],\n          \"genes\": [\n            \"GLDC\"\n          ]\n        },\n        {\n          \"name\": \"Short-chain fatty acid metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"ACSS2 contributes to cancer cell growth under low-oxygen and lipid-depleted conditions\"\n            }\n          ],\n          \"genes\": [\n            \"ACSS3\"\n          ]\n        },\n        {\n          \"name\": \"Lipogenic fatty acid desaturation and synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"SCD and ELOVL enzymes support lipid synthesis and membrane remodeling\"\n            }\n          ],\n          \"genes\": [\n            \"SCD5\",\n            \"ELOVL2\"\n          ]\n        },\n        {\n          \"name\": \"Glutamate-glutamine cycle and neurotransmitter homeostasis\",\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"SLC1A2 encodes GLT-1/EAAT2, the primary astrocytic glutamate transporter\"\n            },\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Glutamate homeostasis is critical for astrocyte function and regulates astrocyte-neuron interactions\"\n            }\n          ],\n          \"genes\": [\n            \"SLC1A2\"\n          ]\n        },\n        {\n          \"name\": \"Intracellular lipid trafficking and sterol synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"Lipid metabolism supports rapid cancer cell proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"OSBP2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Branched-chain amino acid transaminase complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"BCAT1 catalyzes reversible transamination of branched-chain amino acids\"\n            }\n          ],\n          \"genes\": [\n            \"BCAT1\"\n          ]\n        },\n        {\n          \"name\": \"Glycine cleavage system\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"GLDC is part of the glycine cleavage system catalyzing oxidative glycine breakdown\"\n            }\n          ],\n          \"genes\": [\n            \"GLDC\"\n          ]\n        },\n        {\n          \"name\": \"Lipid synthesis and desaturation enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"SCD and ELOVL proteins are ER-resident enzymes modifying fatty acid composition\"\n            }\n          ],\n          \"genes\": [\n            \"SCD5\",\n            \"ELOVL2\",\n            \"ACSS3\"\n          ]\n        },\n        {\n          \"name\": \"Glutamate transporter complexes at the plasma membrane\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"SLC1A2 (GLT-1/EAAT2) is a high-capacity glutamate transporter in astrocytic membranes\"\n            }\n          ],\n          \"genes\": [\n            \"SLC1A2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced anaplerotic replenishment of TCA cycle intermediates supporting biosynthesis under hypoxia\",\n        \"Sustained nucleotide synthesis through glycine catabolism and one-carbon pathway\",\n        \"Altered membrane lipid composition supporting rapid cell division and membrane trafficking\",\n        \"Increased glucose-independent energy production through amino acid catabolism\",\n        \"Dysregulated glutamate homeostasis potentially promoting excitotoxic damage to surrounding neurons and creating immunosuppressive environment\"\n      ],\n      \"evidence_summary\": \"Six metabolic enzyme genes (BCAT1, GLDC, ACSS3, SCD5, ELOVL2, OSBP2) combine with one transporter gene (SLC1A2) to establish metabolic reprogramming. The concentration of amino acid and lipid metabolism genes is striking and particularly relevant given that glioblastomas often exhibit hypoxic microenvironments where oxidative phosphorylation is compromised. BCAT1 is known to be upregulated in high-grade gliomas and to promote poor outcomes, while GLDC dysregulation is a hallmark of malignant gliomas. The presence of multiple lipogenic enzymes (SCD5, ELOVL2) suggests that astrocytomas simultaneously maintain neural-like lipid compositions (which depend on polyunsaturated fatty acids) while supporting rapid cell division.\",\n      \"significance_score\": 0.83,\n      \"citations\": [\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"Glutamate transporter SLC1A2 and amino acid homeostasis critical for astrocyte function\"\n        },\n        {\n          \"source_id\": \"32\",\n          \"notes\": \"ACSS2 (related to ACSS3) promotes cancer cell growth under hypoxia and nutrient restriction\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"Metabolic pathways support neural stem cell maintenance and astrocyte function\"\n        },\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"SKA3-mediated metabolic reprogramming toward glycolysis enables hypoxia tolerance\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"BCAT1 and lipid metabolism genes promote breast cancer progression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"BCAT1\",\n        \"GLDC\",\n        \"ACSS3\",\n        \"SCD5\",\n        \"ELOVL2\",\n        \"OSBP2\",\n        \"SLC1A2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PKM2\",\n          \"HK2\",\n          \"GLUT1\",\n          \"G6PD\",\n          \"LDHA\",\n          \"PFKFB3\",\n          \"GLS\",\n          \"GOT1\",\n          \"GOT2\",\n          \"MDH1\",\n          \"MDH2\",\n          \"ACLY\",\n          \"FASN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"51\",\n            \"notes\": \"Glycolytic enzymes (PKM2, HK2, GLUT1) and biosynthetic enzymes (ACLY, FASN) support cancer cell metabolism\"\n          },\n          {\n            \"source_id\": \"49\",\n            \"notes\": \"Metabolic reprogramming drives hypoxia tolerance through HIF-1alpha pathway\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion Channel Regulation and Astrocytic Electrophysiology\",\n      \"description\": \"Dysregulation of ion channel expression (KCNMA1, KCND2, KCNIP1, TRPM3) and neurotransmitter receptors (CHRM3, P2RY14) altering cellular electrophysiology and response to microenvironmental signals. This program fundamentally changes astrocytoma cell sensitivity to ions, neurotransmitters, and paracrine signals.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Large-conductance calcium-activated potassium channel regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"KCNMA1 (MaxiK) large-conductance calcium-activated potassium channels regulate membrane potential\"\n            }\n          ],\n          \"genes\": [\n            \"KCNMA1\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated potassium channel inactivation kinetics\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"KCNIP1 auxiliary subunits regulate Kv4 channel inactivation and calcium entry window\"\n            }\n          ],\n          \"genes\": [\n            \"KCNIP1\",\n            \"KCND2\"\n          ]\n        },\n        {\n          \"name\": \"Transient receptor potential melastatin channel gating\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"TRPM3 is a polymodal cation channel activated by heat and ligands\"\n            }\n          ],\n          \"genes\": [\n            \"TRPM3\"\n          ]\n        },\n        {\n          \"name\": \"G-protein coupled receptor signaling via muscarinic acetylcholine\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"CDKN2B forms complex with CDK4/CDK6 and prevents their activation through GPCR signaling\"\n            }\n          ],\n          \"genes\": [\n            \"CHRM3\"\n          ]\n        },\n        {\n          \"name\": \"Purinergic receptor signaling and ATP sensing\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"SOCS1 and immune checkpoint molecules regulate cytokine and purinergic signaling\"\n            }\n          ],\n          \"genes\": [\n            \"P2RY14\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Large-conductance calcium-activated potassium channel complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"KCNMA1 forms multimeric channel complexes regulated by calcium and voltage\"\n            }\n          ],\n          \"genes\": [\n            \"KCNMA1\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated Kv4 potassium channel complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"KCND2 and KCNIP1 form functional channel units at the plasma membrane\"\n            }\n          ],\n          \"genes\": [\n            \"KCND2\",\n            \"KCNIP1\"\n          ]\n        },\n        {\n          \"name\": \"TRP melastatin ion channel complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"TRPM3 forms tetrameric ion channel pores in the plasma membrane\"\n            }\n          ],\n          \"genes\": [\n            \"TRPM3\"\n          ]\n        },\n        {\n          \"name\": \"G-protein coupled receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Muscarinic receptors couple to heterotrimeric G-proteins through conformational changes\"\n            }\n          ],\n          \"genes\": [\n            \"CHRM3\",\n            \"P2RY14\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered membrane potential dynamics affecting cell-cell signaling and proliferation sensitivity\",\n        \"Enhanced cellular responsiveness to environmental signals normally ignored by mature astrocytes\",\n        \"Integration of multiple ion and neurotransmitter signals into coordinated cellular responses\",\n        \"Potential hyperexcitability or altered calcium dynamics affecting tumor cell behavior\",\n        \"Changed capacity for potassium buffering potentially disrupting neuronal homeostasis\"\n      ],\n      \"evidence_summary\": \"Five genes encoding ion channels and neurotransmitter receptors (KCNMA1, KCND2, KCNIP1, TRPM3, CHRM3, P2RY14) are present, reflecting dysregulation of astrocytic electrophysiology. While mature astrocytes express ion channels including potassium channels for potassium buffering and gap junction proteins for astrocyte networks, the presence of unusual channels like TRPM3 and neurotransmitter receptors like CHRM3 and P2RY14 suggests aberrant electrophysiological properties. These changes could reflect developmental immaturity or reactivation of channels normally silenced during astrocyte differentiation.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"CCND2 and CDK complex formation via signaling\"\n        },\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"Ion channel genes regulate neural cell electrophysiology\"\n        },\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"SOCS1 regulates immune and cytokine signaling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"KCNMA1\",\n        \"KCND2\",\n        \"KCNIP1\",\n        \"TRPM3\",\n        \"CHRM3\",\n        \"P2RY14\",\n        \"SLC8A1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GNA11\",\n          \"GNAQ\",\n          \"GNAS\",\n          \"GNAI1\",\n          \"GNAI2\",\n          \"GNAI3\",\n          \"GPCR\",\n          \"PLCB\",\n          \"AC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"G-protein alpha subunits couple muscarinic receptors to downstream signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell-Cell Communication and Paracrine Signaling\",\n      \"description\": \"Regulation of inter-cellular communication through transmembrane ligands (JAG1, ALK) and secreted factors that signal to neighboring cells. This program enables coordination of tumor behavior within multicellular foci and manipulation of the tumor microenvironment.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Notch ligand-receptor signaling via JAG1\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"JAG1 and Notch signaling frequently dysregulated in pediatric brain tumors to promote stemness\"\n            }\n          ],\n          \"genes\": [\n            \"JAG1\"\n          ]\n        },\n        {\n          \"name\": \"ALK receptor tyrosine kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GFAP::ALK fusion in infant-type hemispheric gliomas drives potent oncogenic signaling\"\n            }\n          ],\n          \"genes\": [\n            \"ALK\"\n          ]\n        },\n        {\n          \"name\": \"G-protein signaling termination and RGS function\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"SOCS and RGS proteins regulate G-protein signaling and immune responses\"\n            }\n          ],\n          \"genes\": [\n            \"RGS6\",\n            \"RGS17\"\n          ]\n        },\n        {\n          \"name\": \"Rab GTPase-dependent endocytic trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"Endocytic trafficking regulates receptor and ligand processing\"\n            }\n          ],\n          \"genes\": [\n            \"DENND2A\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transmembrane Notch ligand complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"JAG1 forms transmembrane Notch ligand complexes\"\n            }\n          ],\n          \"genes\": [\n            \"JAG1\"\n          ]\n        },\n        {\n          \"name\": \"ALK receptor tyrosine kinase monomers and dimers\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"ALK can form ligand-induced dimers triggering autophosphorylation\"\n            }\n          ],\n          \"genes\": [\n            \"ALK\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced Notch signaling promoting stem cell-like properties and reduced differentiation\",\n        \"ALK-mediated signaling driving proliferation and survival in fusion-positive tumors\",\n        \"Altered G-protein signaling kinetics affecting response to paracrine cues\",\n        \"Dysregulated endocytic trafficking affecting growth factor receptor cycling\"\n      ],\n      \"evidence_summary\": \"Three genes (JAG1, ALK, RGS6, RGS17, DENND2A) encode proteins directly involved in paracrine communication. JAG1 is a Notch ligand whose expression correlates with stemness, while ALK is a receptor tyrosine kinase frequently involved in oncogenic fusions in gliomas. RGS proteins regulate the timing of G-protein signaling, and DENND2A regulates endosomal trafficking of signaling components.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"JAG1, ALK, and Notch signaling dysregulation in pediatric brain tumors\"\n        },\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"RGS and SOCS proteins regulate signaling dynamics\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"JAG1\",\n        \"ALK\",\n        \"RGS6\",\n        \"RGS17\",\n        \"DENND2A\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"NOTCH1\",\n          \"NOTCH2\",\n          \"NOTCH3\",\n          \"NOTCH4\",\n          \"RBPJ\",\n          \"MAML1\",\n          \"NICD\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"5\",\n            \"notes\": \"Notch receptors are required for JAG1-mediated signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Wnt and Notch Signaling Integration\",\n      \"description\": \"Coordinated regulation of canonical and non-canonical Wnt signaling alongside Notch pathway components through shared transcriptional nodes (LEF1, RUNX1) and pathway regulators (RGS6, CTNNBIP1). This program establishes self-renewing progenitor identity and resistance to differentiation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Canonical Wnt/beta-catenin signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"CTNNBIP1 inhibits beta-catenin-LEF1 interaction regulating Wnt signaling\"\n            },\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"Wnt signaling drives canonical pathway activation promoting stemness\"\n            },\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"WNT3A and canonical Wnt signaling promote stemness and proliferation\"\n            }\n          ],\n          \"genes\": [\n            \"LEF1\",\n            \"CTNNBIP1\",\n            \"RUNX1\"\n          ]\n        },\n        {\n          \"name\": \"Non-canonical Wnt signaling (Wnt-Ca2+ and Wnt-PCP)\",\n          \"citations\": [\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"Non-canonical Wnt signaling involves WNT5A and calcium-dependent effectors\"\n            }\n          ],\n          \"genes\": [\n            \"CREB5\"\n          ]\n        },\n        {\n          \"name\": \"Notch signaling pathway cross-regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"Notch signaling cooperates with Wnt pathway in neural progenitor maintenance\"\n            }\n          ],\n          \"genes\": [\n            \"LEF1\",\n            \"RUNX1\",\n            \"CREB5\"\n          ]\n        },\n        {\n          \"name\": \"G-protein signaling regulation linking pathway coordination\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"RGS proteins regulate G-protein kinetics affecting multiple signaling pathways\"\n            }\n          ],\n          \"genes\": [\n            \"RGS6\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"TCF/LEF-beta-catenin transcriptional complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"LEF1 and beta-catenin form nuclear transcriptional activation complexes\"\n            }\n          ],\n          \"genes\": [\n            \"LEF1\"\n          ]\n        },\n        {\n          \"name\": \"Transcriptional co-activator complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"RUNX1 forms complexes with LEF1 and other transcriptional regulators\"\n            }\n          ],\n          \"genes\": [\n            \"RUNX1\",\n            \"CREB5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced stemness and reduced differentiation through canonical Wnt pathway activation\",\n        \"Altered cell migration and EMT-like transitions through non-canonical Wnt signaling\",\n        \"Dysregulated coupling between Notch and Wnt pathways promoting progenitor identity\",\n        \"Increased tumor-initiating cell frequency and therapeutic resistance\"\n      ],\n      \"evidence_summary\": \"Five genes (LEF1, RUNX1, CREB5, RGS6, CTNNBIP1) coordinate Wnt and Notch signaling. LEF1 serves as a central transcriptional node, functioning as a co-factor with beta-catenin in canonical Wnt signaling while also receiving inputs from Notch. RUNX1 cooperates with LEF1 in multiple contexts. The presence of CTNNBIP1, which inhibits beta-catenin-LEF1 interaction, suggests a mechanism for fine-tuning Wnt signaling intensity. RGS6 provides an additional layer of regulation through G-protein signaling modulation.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"5\",\n          \"notes\": \"Wnt and Notch pathway integration in pediatric brain tumor development\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"CTNNBIP1 regulates Wnt/beta-catenin signaling\"\n        },\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"RGS proteins regulate signaling integration\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"RUNX1 cooperates with LEF1 in developmental programs\"\n        },\n        {\n          \"source_id\": \"57\",\n          \"notes\": \"Wnt signaling drives stemness and cytoarchitectural changes\"\n        },\n        {\n          \"source_id\": \"59\",\n          \"notes\": \"WNT3A drives canonical Wnt signaling and stemness\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"LEF1\",\n        \"RUNX1\",\n        \"CREB5\",\n        \"RGS6\",\n        \"CTNNBIP1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CTNNB1\",\n          \"APC\",\n          \"AXIN1\",\n          \"GSK3B\",\n          \"TCF7\",\n          \"NOTCH1\",\n          \"NOTCH2\",\n          \"RBPJ\",\n          \"MAML1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"27\",\n            \"notes\": \"Beta-catenin (CTNNB1) is the core effector of canonical Wnt signaling\"\n          },\n          {\n            \"source_id\": \"57\",\n            \"notes\": \"GSK3B is part of the beta-catenin destruction complex\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"RNA Processing and Post-Transcriptional Gene Regulation\",\n      \"description\": \"Dysregulation of RNA-binding proteins (NOVA1, RBPMS) and numerous long non-coding RNAs (MIR4435-2HG, CHRM3-AS2, ADAMTS9-AS1, HMGA2-AS1, PCDH9-AS2, GNG12-AS1, LINC02742, LINC01138, LINC01798, LINC00266-1, MEG8, ERI1) that collectively control alternative splicing, mRNA stability, and miRNA biogenesis. This program enables rapid remodeling of the proteome in response to microenvironmental changes.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Alternative splicing regulation by RNA-binding proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"NOVA1 regulates alternative splicing of ion channels and synaptic proteins\"\n            }\n          ],\n          \"genes\": [\n            \"NOVA1\",\n            \"RBPMS\"\n          ]\n        },\n        {\n          \"name\": \"MicroRNA biogenesis and function\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Phosphorylation regulates liquid-liquid phase separation affecting miRNA processing\"\n            }\n          ],\n          \"genes\": [\n            \"ERI1\"\n          ]\n        },\n        {\n          \"name\": \"Long non-coding RNA-mediated transcriptional and post-transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"lncRNAs including LINC01068 regulate neural stem cell proliferation and differentiation\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"LINC03091 and LINC03090 dysregulation in psychiatric disorders affects brain development genes\"\n            }\n          ],\n          \"genes\": [\n            \"MIR4435-2HG\",\n            \"CHRM3-AS2\",\n            \"ADAMTS9-AS1\",\n            \"HMGA2-AS1\",\n            \"PCDH9-AS2\",\n            \"GNG12-AS1\",\n            \"LINC02742\",\n            \"LINC01138\",\n            \"LINC01798\",\n            \"LINC00266-1\",\n            \"MEG8\"\n          ]\n        },\n        {\n          \"name\": \"Competing endoribonucleic acid (ceRNA) networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"lncRNAs act as ceRNAs sequestering miRNAs and regulating target gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"MIR4435-2HG\",\n            \"HMGA2-AS1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"RNA-binding protein-mRNA complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"NOVA1 and RBPMS bind mRNAs through sequence-specific RNA recognition domains\"\n            }\n          ],\n          \"genes\": [\n            \"NOVA1\",\n            \"RBPMS\"\n          ]\n        },\n        {\n          \"name\": \"Long non-coding RNA molecular complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"lncRNAs form RNA-protein complexes regulating transcription and RNA processing\"\n            }\n          ],\n          \"genes\": [\n            \"MIR4435-2HG\",\n            \"CHRM3-AS2\",\n            \"ADAMTS9-AS1\",\n            \"HMGA2-AS1\",\n            \"PCDH9-AS2\",\n            \"GNG12-AS1\",\n            \"LINC02742\",\n            \"LINC01138\",\n            \"LINC01798\",\n            \"LINC00266-1\",\n            \"MEG8\"\n          ]\n        },\n        {\n          \"name\": \"Microprocessor complexes (Drosha, DGCR8)\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"Microprocessor complexes are regulated by phosphorylation and other PTMs\"\n            }\n          ],\n          \"genes\": [\n            \"ERI1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated alternative splicing of ion channels and adhesion molecules producing tumor-promoting isoforms\",\n        \"Altered miRNA biogenesis and function changing the landscape of post-transcriptional gene silencing\",\n        \"lncRNA-mediated ceRNA networks sequestering tumor-suppressive miRNAs\",\n        \"Rapid proteome remodeling in response to microenvironmental signals without requiring new transcription\",\n        \"Dysregulation of imprinted genes through altered lncRNA expression affecting cell growth and differentiation\"\n      ],\n      \"evidence_summary\": \"Two RNA-binding protein genes (NOVA1, RBPMS) combine with eleven long non-coding RNA genes and one miRNA biogenesis gene (ERI1) to establish extensive post-transcriptional control. The remarkable concentration of lncRNA genes in the astrocytoma gene list is noteworthy, as these genes are frequently dysregulated in neural development and psychiatric disease. NOVA1 is known to regulate splicing of glutamate receptors, ion channels, and synaptic proteins—precisely the genes that appear dysregulated in this input list (GRIN2B, GRIA3, GRIK2). The presence of MEG8, an imprinted lncRNA, suggests potential dysregulation of imprinted loci, which could contribute to loss of growth control.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\n          \"source_id\": \"29\",\n          \"notes\": \"NEAT1 regulates cell cycle and apoptosis in cancer cells\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Post-translational modifications regulate liquid-liquid phase separation affecting RNA processing\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"LINC01068 regulates neural stem cell proliferation and differentiation\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"LINC03091 and LINC03090 dysregulation in bipolar disorder and potential role in neural development\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"NOVA1\",\n        \"RBPMS\",\n        \"MIR4435-2HG\",\n        \"CHRM3-AS2\",\n        \"ADAMTS9-AS1\",\n        \"HMGA2-AS1\",\n        \"PCDH9-AS2\",\n        \"GNG12-AS1\",\n        \"LINC02742\",\n        \"LINC01138\",\n        \"LINC01798\",\n        \"LINC00266-1\",\n        \"MEG8\",\n        \"ERI1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"DROSHA\",\n          \"DGCR8\",\n          \"DICER\",\n          \"AGO2\",\n          \"AGO1\",\n          \"ARGONAUTE\",\n          \"DHH29\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"43\",\n            \"notes\": \"Microprocessor proteins (Drosha, DGCR8) and DICER are essential for miRNA biogenesis\"\n          },\n          {\n            \"source_id\": \"44\",\n            \"notes\": \"ARGONAUTE proteins mediate miRNA function\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Kinase Signaling and Cell Cycle Control\",\n      \"description\": \"Dysregulation of cyclin-dependent kinases (CDK6, CDK14) and serine/threonine kinases (NEK6, STK17A, STK32A, STK32B) that regulate cell cycle progression, checkpoint control, and response to stress. Combined with kinase inhibitors (CDKN2A, CDKN2B), this program establishes the balance between proliferation and growth arrest.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"G1/S cell cycle progression via CDK-cyclin complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"CCND2 forms complex with CDK4/CDK6 required for G1/S transition\"\n            },\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"CDKN2B inhibitor forms complex with CDK4/CDK6 preventing kinase activation\"\n            },\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"CDKN2A is frequently deleted in tumors and serves as key tumor suppressor\"\n            },\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"CDKN2B encodes cyclin-dependent kinase inhibitor 2B preventing CDK4/CDK6 activation\"\n            }\n          ],\n          \"genes\": [\n            \"CDK6\",\n            \"CDK14\",\n            \"CDKN2A\",\n            \"CDKN2B\"\n          ]\n        },\n        {\n          \"name\": \"Mitotic checkpoint control and spindle dynamics\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"SKA3 regulates spindle kinetochore attachment and mitotic progression\"\n            }\n          ],\n          \"genes\": [\n            \"NEK6\",\n            \"STK32B\"\n          ]\n        },\n        {\n          \"name\": \"Cell death and stress response signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"HDAC inhibitors regulate cell death and proliferation in neurodegenerative disease\"\n            }\n          ],\n          \"genes\": [\n            \"STK17A\"\n          ]\n        },\n        {\n          \"name\": \"Ste20-family serine/threonine kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"Kinases coordinate cell cycle and stress responses\"\n            }\n          ],\n          \"genes\": [\n            \"STK32A\",\n            \"STK32B\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"CDK-cyclin complexes at the cell cycle checkpoint\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"CDK4/CDK6 complexes with D-cyclins regulate G1/S transition\"\n            }\n          ],\n          \"genes\": [\n            \"CDK6\",\n            \"CDKN2B\"\n          ]\n        },\n        {\n          \"name\": \"Mitotic checkpoint complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"SKA3 assembles spindle checkpoint complexes\"\n            }\n          ],\n          \"genes\": [\n            \"NEK6\",\n            \"STK32B\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced G1/S transition and accelerated cell cycle progression\",\n        \"Loss of CDK inhibitor function (CDKN2A/2B deletion) permitting uncontrolled proliferation\",\n        \"Dysregulated mitotic checkpoint control promoting genomic instability\",\n        \"Altered stress-induced cell cycle arrest and apoptosis\",\n        \"Integration of multiple cell cycle signals enabling resistance to growth arrest stimuli\"\n      ],\n      \"evidence_summary\": \"Four cell cycle regulatory genes (CDK6, CDK14, CDKN2A, CDKN2B) are present alongside four serine/threonine kinases (NEK6, STK17A, STK32A, STK32B) regulating checkpoint control and stress responses. The presence of both cyclin-dependent kinases and their inhibitors reflects the balance between proliferation and growth arrest. CDKN2A and CDKN2B are frequently deleted in astrocytomas, removing critical growth brakes. The concentration of kinases suggests that astrocytomas not only accelerate cell cycle progression but also integrate multiple stress and differentiation signals to override normal checkpoints.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"CCND2 and CDK4/6 regulate G1/S transition\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"CDKN2B prevents CDK activation\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"CDKN2A frequently deleted in tumors\"\n        },\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"CDKN2B forms inhibitory complex with CDK4/6\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"HDAC inhibitors regulate cell cycle and death\"\n        },\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"SKA3 and kinase signaling coordinate mitosis and proliferation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CDK6\",\n        \"CDK14\",\n        \"CDKN2A\",\n        \"CDKN2B\",\n        \"NEK6\",\n        \"STK17A\",\n        \"STK32A\",\n        \"STK32B\",\n        \"PRKD1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CCND1\",\n          \"CCND2\",\n          \"CCNE1\",\n          \"CCNA2\",\n          \"CDK1\",\n          \"CDK2\",\n          \"CDK4\",\n          \"RB1\",\n          \"E2F1\",\n          \"E2F2\",\n          \"E2F3\",\n          \"P53\",\n          \"CHEK1\",\n          \"CHEK2\",\n          \"PLK1\",\n          \"AURKA\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"CCND2 forms complexes with CDK4/6\"\n          },\n          {\n            \"source_id\": \"5\",\n              \"notes\": \"TP53 mutations are common in high-grade gliomas\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Signaling Integration Hub and Cross-Talk Regulation\",\n      \"description\": \"Master regulatory genes whose products function as signaling hubs integrating multiple pathways (IQGAP2, KALRN, ARHGEF26, HMGA2, IGF2BP2, IGF2BP3). These genes enable coordinated responses to diverse microenvironmental signals and represent critical nodes where therapeutic intervention could disrupt multiple pathways simultaneously.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Scaffolding protein-mediated signal integration\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"IQGAP1 scaffolds Rac1 signaling and promotes cancer cell motility\"\n            }\n          ],\n          \"genes\": [\n            \"IQGAP2\"\n          ]\n        },\n        {\n          \"name\": \"GEF-mediated cross-talk between RTK and GTPase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"RhoJ inactivation and Rac activation coordinate filopodial dynamics\"\n            },\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Trio GEF activity couples semaphorin signaling with Rho GTPase regulation\"\n            }\n          ],\n          \"genes\": [\n            \"KALRN\",\n            \"ARHGEF26\"\n          ]\n        },\n        {\n          \"name\": \"Stemness and EMT-driving transcriptional networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"HMGA2 promotes stemness and EMT in cancer\"\n            }\n          ],\n          \"genes\": [\n            \"HMGA2\"\n          ]\n        },\n        {\n          \"name\": \"mRNA stability and localization control via RNA-binding proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"IGF2BP proteins regulate mRNA stability of growth-promoting genes\"\n            }\n          ],\n          \"genes\": [\n            \"IGF2BP2\",\n            \"IGF2BP3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"IQGAP scaffolding complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"IQGAP1 forms multimeric scaffolding complexes\"\n            }\n          ],\n          \"genes\": [\n            \"IQGAP2\"\n          ]\n        },\n        {\n          \"name\": \"GEF-Rho GTPase-effector signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Trio forms complexes with CRMP2 and Rho GTPases\"\n            }\n          ],\n          \"genes\": [\n            \"KALRN\",\n            \"ARHGEF26\"\n          ]\n        },\n        {\n          \"name\": \"RNA-binding protein-mRNA complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"IGF2BP proteins bind and stabilize target mRNAs\"\n            }\n          ],\n          \"genes\": [\n            \"IGF2BP2\",\n            \"IGF2BP3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Simultaneous integration of growth factor, adhesion, and stress signals enabling robust proliferation\",\n        \"Cross-activation of RTK and GTPase signaling amplifying proliferation and migration\",\n        \"Maintenance of stemness through HMGA2-driven transcriptional networks\",\n        \"Stabilization of mRNAs encoding growth-promoting genes through IGF2BP-mediated mRNA binding\",\n        \"Robust therapeutic resistance through redundant signaling integration and feedback loops\"\n      ],\n      \"evidence_summary\": \"Five genes (IQGAP2, KALRN, ARHGEF26, HMGA2, IGF2BP2, IGF2BP3) encode master regulators that simultaneously participate in multiple pathways. IQGAP2 scaffolds multiple signaling proteins, KALRN and ARHGEF26 function as GEFs enabling cross-talk between receptor and GTPase signaling, HMGA2 drives stemness and EMT, and IGF2BPs regulate mRNA stability of multiple target genes. The presence of these hub proteins suggests that astrocytomas achieve remarkable robustness through centralized integration of divergent signals.\",\n      \"significance_score\": 0.79,\n      \"citations\": [\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"HMGA2 and IGF2BP proteins promote cancer cell stemness and proliferation\"\n        },\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"RhoJ inactivation promotes cell motility\"\n        },\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Trio couples semaphorin signaling to Rho GTPase regulation\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"IQGAP1 scaffolds Rac1-dependent signaling\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"IQGAP2\",\n        \"KALRN\",\n        \"ARHGEF26\",\n        \"HMGA2\",\n        \"IGF2BP2\",\n        \"IGF2BP3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"RAC1\",\n          \"RHOA\",\n          \"CDC42\",\n          \"PAK1\",\n          \"WASP\",\n          \"A",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/894",
      "https://www.ncbi.nlm.nih.gov/gene/1030",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.ncbi.nlm.nih.gov/gene/3696",
      "https://www.nature.com/articles/s41698-025-01151-w",
      "https://www.ncbi.nlm.nih.gov/gene/3611",
      "https://www.ncbi.nlm.nih.gov/gene/2903",
      "https://pubmed.ncbi.nlm.nih.gov/41274436/",
      "https://www.ncbi.nlm.nih.gov/gene/10395",
      "https://www.nature.com/articles/s41380-025-03384-4",
      "https://www.ncbi.nlm.nih.gov/gene/4323",
      "https://www.ncbi.nlm.nih.gov/gene/93663",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.ncbi.nlm.nih.gov/gene/5156",
      "https://pubmed.ncbi.nlm.nih.gov/41267067/",
      "https://pubmed.ncbi.nlm.nih.gov/41367497/?fc=None&ff=20251215163942&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/2263",
      "https://www.nature.com/articles/s41419-025-08292-7",
      "https://www.ncbi.nlm.nih.gov/gene/7422",
      "https://www.ncbi.nlm.nih.gov/gene/24842",
      "https://www.ncbi.nlm.nih.gov/gene/283",
      "https://www.ncbi.nlm.nih.gov/gene/1385",
      "https://www.ncbi.nlm.nih.gov/gene/7471",
      "https://www.ncbi.nlm.nih.gov/gene/6667",
      "https://www.ncbi.nlm.nih.gov/gene/56998",
      "https://www.ncbi.nlm.nih.gov/gene/8651",
      "https://www.ncbi.nlm.nih.gov/gene/283131",
      "https://www.ncbi.nlm.nih.gov/gene/407021",
      "https://www.ncbi.nlm.nih.gov/gene/1029",
      "https://www.ncbi.nlm.nih.gov/gene/55902",
      "https://www.ncbi.nlm.nih.gov/gene/57381",
      "https://www.ncbi.nlm.nih.gov/gene/2180",
      "https://www.ncbi.nlm.nih.gov/gene/998",
      "https://www.nature.com/articles/s42003-025-08988-8",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=861",
      "https://www.nature.com/articles/s41420-025-02908-9",
      "https://www.ncbi.nlm.nih.gov/gene/10512",
      "https://www.ncbi.nlm.nih.gov/gene/861",
      "https://www.ncbi.nlm.nih.gov/gene/23411",
      "https://www.nature.com/articles/s42004-025-01773-y",
      "https://www.nature.com/articles/s41380-025-03421-2",
      "https://www.nature.com/subjects/post-translational-modifications/ncomms",
      "https://www.nature.com/articles/s41598-025-26426-x",
      "https://www.ncbi.nlm.nih.gov/gene/7507",
      "https://www.nature.com/articles/s41419-025-08270-z",
      "https://www.ncbi.nlm.nih.gov/gene/5888",
      "https://www.nature.com/articles/s41598-025-27560-2",
      "https://pubmed.ncbi.nlm.nih.gov/41334166/",
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.nature.com/articles/s41593-025-02100-3",
      "https://www.ncbi.nlm.nih.gov/gene/5879",
      "https://www.nature.com/articles/s12276-025-01507-z",
      "https://www.ncbi.nlm.nih.gov/gene/5594",
      "https://www.ncbi.nlm.nih.gov/gene/89780",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": null
  }
}